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Abstract
Variegate porphyria (VP; OMIM 176200) is caused by mutations in the
protoporphyrinogen oxidase gene (PPOX) and is inherited as an autosomal
dominant trait, displaying incomplete penetrance. Manifestation of VP includes
photosensitivity and potentially fatal acute porphyric attacks. The incidence of
VP in South Africa is the highest in the world due to a founder effect. In 1960
Geoffrey Dean estimated the frequency of VP to be 0.3% in the Caucasian South
African population. However, this estimate is questionable on the grounds of
genealogical and biochemical methods used, and as indicated by more recent
records from diagnostic laboratories reported here.
The aim of this study was to determine the frequency of the VP founder mutation
(R59W) within two South African populations (Caucasian and mixed ancestry) by
means of a highly specific DNA test. Various methods of blood sample
collection, DNA isolation and R59W mutation detection, suitable for a large-scale
population-screening study, were evaluated. Blood samples were obtained from
4 072 participants at blood transfusion clinics, pathology clinics and maternity
wards from three provinces within South Africa. Blood sample collection on FTA
cards (Whatman BioScience) with subsequent DNA isolation and SSCP analysis
were found to be the most appropriate methods.
Four of the participants tested were positive for the R59W mutation. All four were
from the 3 233 Caucasian individuals tested while three of these were Afrikaans-
speaking, confirming the high prevalence of the founder mutation in the South
African Afrikaans-speaking Caucasian population (Afrikaner), as previously
reported. One of the two adult R59W positive participants was unaware of her
carrier status, in accordance with incomplete penetrance of the trait recently
estimated as 60%. The mother of one of the newborn babies found to be R59W
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positive was also not aware of VP in the family, indicating that ignorance
regarding VP status in South Africa is a matter of some concern.
The estimated frequency of 0.12% (4 / 3 233) for the R59W mutation is
significantly lower than the frequency of 0.3% estimated previously, and analysis
of the different populations sampled yielded interesting results. Only one of 2 093
(0.05%) participants in the Caucasian blood transfusion sample was mutation-
positive. It is possible that the sample from this group was not unbiased, as
porphyries were discouraged to donate blood in the past. One of 761 (0.13%)
Caucasian participants from pathology clinics was mutation-positive. This
sample was probably not unbiased either, since suspected porphyries are
referred to these clinics by physicians. Two of 379 (0.53%) Caucasian newborn
individuals tested positive, yielding a much higher frequency than the previous
estimate by Dean. Although the sample size was very small, it was probably
unbiased and therefore provides the best estimate. It is suggested that the
sample size of this group be increased in order to improve the accuracy of the
founder mutation frequency estimation in South Africa and to determine whether
the issue of underdiagnosis and the resulting risk of potentially fatal acute attacks
should be addressed by appropriate genetic testing in the future.
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Opsomming
Variegate porfirie (VP; OMIM 176200) word veroorsaak deur mutasies in die
protoporforinogeen oksidase geen (PPOX) en vertoon 'n outosomaal dominante
oorerwingspatroon met onvolledige penetransie. Die manifestasie van VP sluit
fotosensitiwiteit en potensieël noodlottige akute aanvalle in. Die voorkoms van
VP in Suid-Afrika is die hoogste in die wêreld as gevolg van 'n stigtereffek. In
1960 het Geoffrey Dean die frekwensie van VP in die Suid-Afrikaanse
Kaukasiese populasie beraam as 0.3%. Hierdie beraming word egter
bevraagteken op grond van die genealogiese en biochemiese metodes wat
gebruik is, soos aangedui deur meer onlangse bevindinge van diagnostiese
laboratoria.
Die doel van hierdie studie was om die frekwensie van die VP stigtermutasie
(R59W) in twee Suid-Afrikaanse populasies (Kaukasiese en van gemengde
herkoms) deur middel van 'n hoogs spesifieke DNS toets te beraam. Verskeie
metodes van bloedmonsterinsameling, DNS isolasie en R59W mutasie deteksie,
geskik vir 'n grootskaalse populasiesifting studie, is ondersoek. Bloedmonsters
van 4 072 vrywilligers by bloedoortappingsklinieke, patologieklinieke en
kraamsale van drie provinsies binne Suid-Afrika is verkry. Daar is gevind dat
bloedmonsterversameling op FTA kaartjies (Whatman BioScience) met
gepaardgaande DNS isolasie en SSCP analise die mees effektiewe metodes is.
Vier van die individue wat getoets is, was positief vir die R59W mutasie. AI vier
was afkomstig van die 3 233 Kaukasiese monsters, terwyl drie
Afrikaanssprekend was, en dus die hoë voorkoms van die stigtermutasie in die
Suid-Afrikaanse Afrikaansspekende Kaukasiese bevolking (Afrikaner) bevestig.
Een van die twee volwasse R59W positiewe individue was onbewus van haar
draer status, wat ooreenstem met die onlangse beraming van 'n 60%
penetransie vir VP. Die ma van een van die R59W positiewe pasgebore babas
III
Stellenbosch University http://scholar.sun.ac.za
was ook onbewus van VP in die familie. Hierdie uitslae impliseer dat onkunde
aangaande VP status "n rede tot kommer in Suid-Afrika mag wees.
Die beraamde frekwensie van 0.12% (4/3233) vir die R59W mutasie was baie
laer as die vorige beraamde frekwensie van 0.3%. Analise van die verskillende
monsterpopulasies het egter interessante resultate gelewer. Slegs een van
2 093 (0.05%) deelnemers in die Kaukasiese bloedoortappingsgroep was
mutasie-positief. Dit is moontlik dat die bloedmonsters verkry vanaf hierdie bron
nie ongeselekteerd was nie, aangesien porfirielyers in die verlede afgeraai is om
bloed te skenk. Een van 761 (0.13%) Kaukasiese individue verkry van
patologieklinieke was mutasie-positief. Hierdie groep was ook nie
ongeselekteerd nie, aangesien geneeshere moontlike porfirielyers na hierdie
klinieke verwys. Twee van 379 (0.53%) Kaukasiese pasgebore babas het
positief getoets, wat "n baie hoër frekwensie is as wat deur Dean beraam is.
Alhoewel hierdie monsterpopulasie baie klein was, was dit ongeselekteerd en het
dit waarskynlik die mees akkurate beraming gelewer. Daar word dus voorgestel
dat die aantal monsters in hierdie groep vermeerder word om "n meer akkurate
beraming van die stigtermutasie in Suid-Afrika te verkry en sodoende te bepaal
of onderdiagnose en die gepaardgaande risiko van noodlottige akute aanvalle in
die toekoms deur gepaste genetiese toetsing aangespreek behoort te word.
IV
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Chapter One Introduction
1. 1 The Porphyrias
The porphyrias are a group of disorders of porphyrin or porphyrin-precursor
metabolism in the haem biosynthesis pathway, resulting from the inherited or
acquired dysfunction of the enzymes controlling the porphyrin-haem biosynthetic
pathway, leading to overproduction of porphyrins and their precursors (Bissell,
1979; Bickers et al., 1993). Haem is one of the most versatile prosthetic groups
in the cell. Along with specific associated protein structures, it mediates oxygen
transport and storage, generates cellular energy and the formation of cGMP,
H202, NO, prostaglandins, bile salts and steroid hormones. It performs some
reduction, degradation and detoxification reactions and also induces protein
synthesis and cell differentiation. Some of the better known haem containing
proteins are hemoglobin, myoglobin, some of the cytochromes, cytochrome P450
oxidases and peroxidases (Dean, 1963; Bissell, 1979).
There are eight enzymes involved in the synthesis of haem, the first one and last
three located in the mitochondria, while the rest are present in the cytosol. The
synthesis pathway of haem is illustrated in Figure 1.1. All cells are able to
produce haem, however, in man most haem is synthesized in the liver and bone
marrow. Haem synthesis is initiated in the mitochondrion by the condensation of
succinyl-CoA and glycine to form ê-amlnolevulinate acid (ALA). In the cytosol
two ALA molecules condense to form the monopyrrole porphobilinogen (PSG).
Four molecules of PBG are assembled and then rearranged to form the first
tetrapyrrolic porphyrinogen intermediate, uroporphyrinogen-III. Stepwise
decarboxylation of uroporphyrinogen to coproporphyrinogen-III follows.
Coproporphyrinogen-III then enters the mitochondrion where it undergoes
oxidated decarboxylation to yield protoporphyrinogen-IX which is in turn oxidized
2
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Chapter One Introduction
to protoporphyrin-IX. This is followed by the insertion of ferrous iron to yield
haem (Elder, 1982).
Haem synthesis is normally an extremely efficient, tightly controlled process.
Less than 2.5% of the ALA entering the pathway is lost and the amount of haem
produced closely matches the need of the body (Neuberger, 1980). This implies
that the pathway is subject to some form of feedback control, principally at the
level of ALA synthase, the rate-determining enzyme of the pathway. Any defect
in haem synthesis which results in a relative shrinking of the haem pool will
derepress ALA synthase in order to achieve a new steady state of haem
synthesis. This increase in ALA synthase, while partially restoring the haem
pool, also stresses the synthetic chain to a point where there is an additional
accumulation of substrate proximal to the partial block (Kappas et al., 1989).
A defect in any of the eight enzymes normally leads to a 50% decrease in activity
of the deficient enzyme (Bissell, 1979; James and Hift, 2000). This causes an
accumulation of the porphyrin precursors and/or the porphyrins themselves.
These metabolites can often be detected in the body or after excretion in the
urine and/or faeces. Before the advent of molecular diagnostic tests for some of
the porphyrias, biochemical assays were the methods commonly used for
diagnostic purposes. The type of porphyria that would affect an individual was
determined by the specific enzymatic defect in the metabolic pathway (Bissell,
1979).
Except for congenital erythropoietic porphyria (CEP) and 8-aminolevulinic acid
dehydratase porphyria (ALAD), all of the porphyrias have a dominant mode of
inheritance. Porphyria cutanea tanda (PCT) is thought to be either dominant or
acquired from external effects such as excessive alcohol consumption, iron
overloads, polychlorinated hydrocarbons and oestrogens (Meissner et al., 1987).
3
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Figure 1.1: The haem biosynthetic pathway showing the sites of enzymes and their
resulting deficiencies in the porphyrias. (Adapted from Deacon and Elder, 2001)
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The porphyrias are subdivided into acute and non-acute forms, based on the
occurrence of acute and recurrent neurological attacks. The acute porphyrias
include acute intermittent porphyria (AlP) (Goldberg, 1959; Lindberg et al., 1996),
hereditary coproporphyria (HCP) (Berger and Goldberg, 1955) and variegate
porphyria (VP) (Dean, 1963; Cochrane and Goldberg, 1968; Mustajoki, 1978).
The non-acute porphyrias are congenital erythropoietic porphyria (Levin, 1968;
Tanigawa et al., 1996), ê-aminolevulinic acid dehydratase porphyria (Doss et al.,
1979), porphyria cutanea tarda (Hofstad et al., 1973; Wu et al., 1996) and
congenital erythropoietic protoporphyria (Peterka et al., 1965).
The possibility of an acute attack occurring is very difficult to define. Some
patients with AlP and VP might never have an acute attack. There is evidence
that there are a number of factors that might increase the probability for an acute
attack. Drugs, alcohol (acute abuse), physiological hormone fluctuations,
infection, certain diets (normally low in caloric intake) and stress may induce an
acute attack (Frank and Christiano, 1997; Moore and Hift, 1997).
Many enzyme-inducing drugs may be triggers of an acute attack. These drugs
can either demand an increased haem production (by inducing the transcription
of ALA synthetase directly through mRNA, interfering with the haem synthetic
pathway or increasing utilization), or cause a failure in the haem inhibitory
feedback control on ALA synthetase production (Hift et al., 1993; James and Hift,
2000). While accumulation of early haem precursors, ALA and PBG, are
generally associated with acute attacks, late intermediates, the porphyrins, are
associated with skin lesions. Porphyrin molecules are ring structures that absorb
visible light, generating exited states. Excessive concentrations of porphyrins
exposed to daylight, more specifically wavelengths of about 400 nm, generate
free radicals with consequent lipid peroxidation and protein cross-linking, leading
5
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to damage to tissues, cells, sub-cellular elements and biomolecules (Sandberg
and Romslo, 1981; Lim and Sassa, 1993).
1.2 Variegate Porphyria (VP)
Variegate porphyria (OMIM 176200), one of the acute hepatic porphyrias, is
characterized by deficiencies in the protoporphyrinogen oxidase enzyme (PPO;
EC 1.3.3.4) and is usually inherited as an autosomal dominant trait displaying
incomplete penetrance, as not all persons carrying a mutation in the
protoporphyrinogen oxidase gene (PPOX) develop the clinical phenotype
(Grandchamp et al., 1996; Frank and Christiano., 1997). In heterozygotes, PPO
activity is decreased by - 50% (Eales et al., 1980). The PPO enzyme, localized
on the cytosolic surface of the inner mitochondrial membrane, catalyzes the six-
electron oxidation of protoporphyrinogen IX to protoporphyrin IX, using molecular
oxygen (Bickers et al., 1993; Dailey and Dailey, 1996).
Apart from HCP, VP is the only porphyria to be associated with both the acute
and cutaneous types of clinical features. A substantial, though unknown portion
of the gene carriers are asymptomatic throughout their lives, and most gene
carriers are asymptomatic before puberty. The most characteristic feature of VP
is increased photosensitivity, subepidermal blistering with subsequent milia
formation and overly fragility of skin in sun-exposed areas such as the face and
the back of the hands, less commonly also the arms, legs and feet (Bickers et al.,
1993). When levels of the more hydrophilic porphyrins (uroporphyrin, the 7- to 5-
carboxyl porphyrins and coproporphyrin) are predominantly accumulated, less
rapid development of porphyrin-mediated phototoxic lesions occurs, as in VP.
Mechanical fragility and subepidermal blistering, with subsequent milia formation
and scarring of the light-exposed skin are common (Poh-Fitzpatric, 1998). The
6
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epidermis becomes detached form the dermis even with minor trauma, leading to
bulla formation and erosions. These lesions heal slowly and often result in
pigmented scars (Day, 1986). Homozygous inheritance of VP, unlike that of
heterozygous VP, has an onset of symptoms in early childhood, and mental or
growth retardation, chronic skin changes and deformed digits due to cutaneous
photosensitivity, as well as seizures, are not uncommon (Bickers et al., 1993;
Roberts et al., 1995).
Avoidance of sunlight exposure, as far as possible, is the most effective method
of evading the skin conditions associated with VP. Sensible clothing should be
worn and only sunscreens containing zinc oxide or titanium dioxide must be
used. These sunscreens filter out the longer wavelengths of light (Kirsch et al.,
1998).
An acute attack is a life-threatening condition of which presentations have been
reported between the ages of 7 and 75 (Jensen et al., 1995). During an acute
attack, an increase in the excretion of the porphyrin precursors 8-aminolevulinic
acid and porphobilinogen occurs in the urine. In the faeces, an increase in the
excretion of protoporphyrin and, to a lesser extent, of coproporphyrin is observed
(Dean and Barnes, 1959; Eales, 1963; Da Silva et al., 1995). The symptoms of
the acute attack are basically the same for all of the acute porphyrias. Signs and
symptoms include severe abdominal pain, neuropsychiatric manifestations,
constipation, diffuse pain, vomiting, hypertension, tachycardia, fever,
convulsions, sensory loss and neuromuscular weakness which may progress to
quadriparesis and respiratory failure that can lead to coma and death. Although
rarely seen unless the attacks have been multiple or for a long duration,
permanent neurological lesions, especially parasympathetic dysfunction, can
occur. During acute attacks a marked decrease in the levels of sodium, chloride,
7
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calcium and potassium in the blood is also observed (Crimlisk, 1997; Frank and
Christiano, 1997; James and Hift, 2000).
Today the observed frequency of acute attacks, and especially resulting fatalities
(which were estimated to be as high as 10%), are rare, because public
knowledge and healthcare regarding the disease have improved (Lip et a/., 1993;
Kirsh et a/., 1998). Normally acute attacks can be controlled, but this is variable
and depends on the time delay from the onset of the attack to the point where
treatment starts (Dean and Barnes, 1955; Dean, 1963; Eales et a/., 1980; Moore,
1980; Meissner et a/., 1987).
For the treatment of acute attacks, the first and most important intervention is to
avoid factors that are known to precipitate the attacks (Sassa, 2002). No
prophylactic therapy is available, but a number of steps can be taken if an acute
porphyric attack does occur: As a first step, any possible precipitating factors
should be withdrawn. As nausea and vomiting usually accompany the acute
attack, sufficient hydration should be ensured. Oral carbohydrate supplements
should be given to the patient, as carbohydrate loading can suppress porphyrin
synthesis. If the supplement cannot be given orally, a dextrose-saline infusion
can be administered (James and Hift, 2000).
Haematin, a drug found to be effective for an acute attack, can be administered.
Haematin is thought to supplement the intracellular free haem pool and thus
repress ALA synthetase (James and Hift, 2000). Unfortunately this drug is
unstable and can cause renal failure, thrombophlebitis and dose-related
coagulopathy (Bissell, 1988; Ashley, 1996). Haem arginate, a drug with similar
effect, does not have the adverse effects attributed to haematin (Mustajoki and
Nordmann, 1993). Another drug, somatostatin, decreases the tempo at which
ALA synthetase is produced, and together with plasmaphoresis, has been used
8
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successfully in reducing pain and producing complete remission of symptoms in
seven porphyric patients with acute attacks (Medenica et aI., 1997; James and
Hift, 2000).
Opiates can be given to diminish the pain, and the patient can be sedated with
phenothiazines. Nausea and vomiting also respond to this drug. Beta-
adrenergic blockers can be used to control tachycardia and hypertension, and
may also decrease the activity of ALA synthetase. If convulsions occur,
diazepam and clonazepam may be used, where most other anticonvulsants are
contra-indicated (James and Hift, 2000).
1.2.1 The Protoporphyrinogen Oxidase Gene (PPOX)
VP is caused by a molecular lesion in PPOx. This gene was first mapped to
chromosome 14q32 by Bissbort et al. in 1988, but this map position could not be
confirmed in a subsequent linkage study (Warnich et aI., 1996a). More recently
PPOX was localized on chromosome 1q22-23 by means of fluorescence in situ
hybridization (FISH) with a genomic clone of the gene (Taketani et aI., 1995). A
publication by Roberts et al. (1995) supported the map location on chromosome
1, determined by means of microsatellite markers and multipoint linkage analysis,
as well as FISH.
PPOX consists of 13 exons and 12 introns and spans - 5kb (Roberts et aI., 1995;
Taketani et aI., 1995). The coding region of the gene spans 1 431 nucleotides
and its mRNA (including a 5' and 3' untranslated region) spans 1.8kb, encoding a
477 amino acid protein with a calculated molecular mass of 50.8 kilodaltons
(Nishimura et aI., 1995; Dailey and Dailey, 1996).
9
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The molecular heterogeneity of VP is vast, of which the mutational cause include
single base substitutions (transitions and transversions) as well as deletions and
insertions in PPOX, often resulting in unique mutations in different families (Frank
and Christiano, 1997; Whatley et aI., 1999). Von Und Zu Fraunberg et al. (2002)
reported that 111 mutations in PPOX have been reported worldwide and that no
mutational hot spots have been identified. Of these mutations, 38 (34%) are
small insertions or deletions, 44 (40%) are missense mutations, 17 (15%) are
invariant nucleotides at splice sites, 1 (1%) is a gross deletion, and 11 (10%)
create stop codons.
1.2.2 Biochemical Testing
The decreased activity of PPO in VP results in an increased activity of the initial
and rate limiting enzyme of the haem biosynthetic pathway, ALA synthase in the
liver, thus leading to overproduction and increased excretion of porphyrins and
porphyrin precursors. Certain drugs, such as barbiturates and sulphonamides as
well as a reduced caloric intake during dieting or fasting, lead to an induction of
the hemoprotein cytochrome P450 (Moore and Hift, 1997). The increased
synthesis of cytochrome P450 leads to an enhanced haem demand, followed by
the decrease of the regulatory haem pool and an induction of ALA synthetase.
As the induction of ALA synthetase leads to an increase of porphyrins and
porphyrin precursors up to the step of the PPO deficiency underlying VP, VP
usually presents with a distinct porphyrin excretion pattern, making it possible to
distinguish it from other types of porphyrias by means of quantitative analyses of
blood, stool and urine samples (Dailey and Dailey, 1996).
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The exact nature of a porphyria can be determined by high-performance liquid
chromatography (HPLC) or thin-layer chromatography (TLC) of porphyrins
extracted from stool, urine and blood. The early haem precursors are largely
water-soluble and are therefore found in the urine, while the distal intermediates
are hydrophobic and are found in the stool. The diagnosis is made on finding the
typical pattern of excretion for VP. See Kirsch et al. (1998) for typical stool
porphyrin data.
However, biochemical testing is not always accurate, as the extracted porphyrin
concentrations vary widely within and between individual patients, and stool
porphyrin levels do not reflect intracellular porphyrin levels accurately (Kirsch et
aI., 1998). Biochemical testing for VP with urine samples are ineffective, as the
urinary porphyrin excretion found in non-acute VP patients is highly variable and
may be completely normal. The most consistent changes are mild elevations in
copro- and uroporphyrin, but these are only significantly raised in about 30% of
non-acute VP subjects. There are, however, significant elevations in the
concentration of all urinary porphyrins during the acute attack of VP (Frank and
Christiano, 1997).
The chromatographic analysis of plasma porphyrins are generally troublesome,
but fluorescence emission spectra between 621 and 627 nm, when plasma
samples are excited at 405 nm, is a highly specific and sensitive marker for VP
(Corey et aI., 1980; Poh-Fitzpatrick, 1980; Long et aI., 1993). Porphyrin
abnormalities may, however, still occur in lead poisoning, sideroblastic and
haemolytic anaemia, iron deficiency, renal failure, cholestasis, liver disease and
gastrointestinal hemorrhage (Lim et aI., 1992).
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1.2.3 History of VP in South Africa
The incidence of variegate porphyria in South Africa is the highest in the world
and the disease is one of the most common monogenic inherited disease in
South Africa (Eales et al., 1980). During the late 1940s to the mid 1960s,
Geoffrey Dean traced the history of VP in South Africa back to the marriage
between Gerrit Jansz van Deventer, one of 40 free burghers in the Cape of Good
Hope community, and Ariaantje Adriaansse, or Jacobs (personal communication,
J van Deventer), an orphan from Rotterdam sent to the Cape as one of a group
of young Dutch women as potential wives for the free burghers, in 1688 (Dean
and Barnes, 1955; Dean, 1963; Dean, 1971; Eales et al., 1980; Meissner et ai,
1987; Stine and Smith, 1990).
There was no selective pressure against VP, and because of the healthiness and
fecundity of the descendants, the disease was easily established within the
families in the closed community (Eales et al., 1980). During the 1800s, the
community was almost totally cut off from Europe and in only 85 years the
population size increased from ± 1 000 to 17 000 (Jenkins, 1996), thus the
disease became common among Caucasian Afrikaans-speaking South Africans
(Afrikaners). Today, the disease is not confined to the Afrikaner anymore, but
because of admixture it is also present in the English-speaking Caucasian
population as well as in the population of mixed ancestry (Coloureds).
The last quarter of the 19th century witnessed the discovery of modern
pharmaceutical agents and changed the nature of VP. The first published
description of a South African patient with acute porphyria appeared in the
University of Cape Town medical students' journal, I'nyanga, in October 1939.
The authors were medical students Lennox Eales and Jack Chait. H.D. Barnes
of the South African Institute for Medical Research was the first to describe a
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series of cases of 'porphyrinuria' in South Africa (Barnes, 1951; Jenkins, 1997).
Barnes, together with Geoffrey Dean, a Port Elizabeth physician who had
recognized that the disease could manifest with skin lesions, acute attacks or
both, called it 'porphyria variegata' and 'South African genetic porphyria' (Dean
and Barnes, 1955). Dean's genealogical studies subsequently identified the
founding couple from which South African VP patients are descended (Dean,
1971).
About 3 in every 1000 Caucasian South Africans, or 1 in every 350 Caucasians
of the Eastern Cape, are thought to be affected by the disease (Dean, 1960; Day,
1986; Bickers et ai, 1993). In a preliminary study by Dean and Barnes (1958),
1 253 Caucasians, consisting of patients from a mental institute and nurses from
four hospitals in the Eastern Cape, were tested for VP by means of biochemical
analysis of urine and stool samples. They concluded that about 1% of South
African Caucasians may be carriers of the VP founder mutation.
Then, in a follow-up study between 1 April 1959 and 31 March 1960,6458 stool
samples from patients admitted to the Provincial Hospital in Port Elizabeth and
St. Joseph's Hospital (also in Port Elizabeth) were biochemically tested for VP
prior to administration of thiopentone. A small fragment of stool on a glass rod or
wooden stick was inserted into a test tube containing 2 ml of equal parts of amyl
alcohol, glacial acetic acid and ether. The solvent was stirred until a light-brown
colour was reached, and the liquid was subsequently decanted into a clean test
tube. By examining the sample in UV light using a Wood's filter, porphyric stool
showed a brilliant pink fluorescence, while a normal sample was green or gray.
Stool samples of patients detected by the routine test were sent for quantitive
analysis of the stool porphyrins. In this 12-month study, 29 out of 6 458 patients
tested were diagnosed with VP, therefore about one in every 223 patients tested.
As the number of porphyrics administered to hospital was likely to be higher than
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that in the general population (because of acute attacks), Dean estimated the
frequency of VP to be one in 350 among the Caucasian population of the Eastern
Cape (Dean, 1960).
It was estimated that 10 000 - 20 000 South Africans were affected by VP in the
1960s (Dean, 1960; Eales et al., 1980). Because of the mixing with the more
recent immigrants from Britain and other countries, the VP founder gene can be
expected to be present in members derived from these populations too (Jenkins,
1997). It is thus not restricted to the Afrikaner population, which is generally seen
as the descendants of the early settlers, any more. Some reports estimate that
80% of VP carriers are undiagnosed, and the disease thus poses a serious risk
in terms of potentially fatal acute attacks (Day, 1986; Grandchamp et al., 1996).
Up to 40% of these individuals are 'silent' gene carriers, not showing clinical or
biochemical signs of the disease other than the reduced activity of
protoporphyrinogen oxidase (Day, 1986). Porphyria cutanea tarda and acute
intermittent porphyria are also common in South Africa, but not as common as
VP (Meissner et al., 1987).
1.2.4 The R59W Mutation
The mutation that either Ariaantje Adriaansse (or Jacobs) or Gerrit Jansz van
Deventer brought into South Africa, and which today is regarded as a founder
mutation, is the R59W mutation in PPOx. It consists of a C to T transition in
exon 3 of the gene, resulting in an arginine to tryptophan substitution in codon 59
of PPOX (Meissner et al., 1996; Warnich et al., 1996b). By means of linkage
disequilibrium and haplotype analysis, Groenewald et al. (1998) showed that the
R59W mutation in South Africa is not due to multiple mutation events on a
common haplotype, but to a common ancestor in the majority of cases.
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The R59W mutation is situated in the FAD dinucleotide-binding motif of the
encoding enzyme, resulting in a disruption in the protein and a subsequent
virtually undetectable catalytic rate (Dailey and Dailey, 1996; Meissner et al.,
1996). The mutation was also found to alter a ,B-amphiphatic region of the wild
type protein, which might cause a disruption in the protein structure (Warnich et
al., 1996b). The mutation abolishes an Aval restriction site and creates a Styl
restriction site in exon 3 (Meissner et al., 1996; Warnich et al., 1996b), which
allows for a simple diagnostic test.
R59W was found to be present in 26 of 27 South African VP families (96%)
investigated by Meissner et al. (1996) and in 15 of 17 families (88%) studied by
Warnich et al. (1996b). Except for the R59W mutation, nine other mutations
causing VP have been identified in South Africa, namely H20P (Warnich et al.,
1996b; Hift et al., 1997), R168C (Meissner et al., 1996; Warnich et al., 1996b),
537deiAT (Corrigall et al., 1998), Y348C and R138P (Corrigall et al., 2000) and
V290M, L15F, c769deIG;770T>A and Q375X (Corrigall et al., 2001). These
other mutations are very rare and were only detected in single families.
1.3 Population Screening Studies
In any population screening program certain requirements must be met.
Strachan and Read (1999) summarize them as follows:
15
Stellenbosch University http://scholar.sun.ac.za
Chapter One Introduction
1. A positive result must lead to some useful action, for example
a. Preventative treatment, such as a special diet for phenylketonuria.
b. Review and choice of reproductive options in cystic fibrosis carrier
screening.
2. The whole project must be socially and ethically acceptable
a. Subjects must opt in with informed consent.
b. Screening without counseling is unacceptable.
c. There must be no pressure to terminate affected pregnancies.
d. Screening must not be seen as discriminatory.
3. The test must have a high sensitivity and specificity
a. Tests with many false negatives undermine confidence in the program.
b. Tests with many false positives, even if these are subsequently filtered
out by a definitive diagnostic test, can create unacceptably high levels
of anxiety among normal people.
4. The benefits of the program must outweigh its costs
a. It is unethical to use limited health care budgets in an inefficient way.
When a large sample is tested, special methodology is also needed for the
collection and storage of the sample, the extraction of DNA and the assay used
for mutation detection. These methods must take into consideration the cost as
well as the time needed to test an individual. The following section contains a
few examples of population screening studies.
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1.3.1 Collection of Samples
1.3.1.1 Guthrie Cards
a) Hamvas et aJ. (2001)
To determine the population-based frequency of a rare mutation, the 121ins2
mutation in the surfactant protein B gene, Hamvas et aJ. (2001) obtained a
sample of 10 044 on Guthrie cards from the Missouri Department of Health.
b) Olynyk et aJ. (1999)
To assess the prevalence and clinical expression of the hemochromatosis (HFE)
gene, a population based study in Busselton, Australia was conducted.
Hereditary hemochromatosis is associated with homozygosity for the C282Y
mutation in the HFE gene on chromosome 6, elevated serum transferring
saturation and excess iron deposits throughout the body. Blood from 3011
unrelated Caucasian adults were collected on Guthrie cards to screen for the
presence or absence of the C282Y mutation and the H63D mutation (which may
contribute to increased hepatic iron levels).
c) Todorava et aJ. (1999)
Four hundred Gypsy newborns from northeast Bulgaria were screened for
C283Y, a point mutation in the ~SG gene (13q12), which among others causes
limb-girdle muscular dystrophy type 2C. This autosomal recessive disorder is
clinically manifested as an early onset, severe Duchenne-like muscular
dystrophy. Blood from the 400 Gypsy newborns were obtained on Guthrie cards
from a previous Phenylketonuria mass screening program.
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1.3.1.2 Whole Blood
a) Pastinen et al. (2001)
Thirty one rare and common disease mutations underlying 27 clinical phenotypes
were monitored in a sample of 2 151 whole blood specimens from four
geographical areas representing early and late settlement regions of Finland.
Some of these samples were obtained as isolated DNA, 510 from a previous
large epidemiological population-based study and 495 samples from the Finnish
Twin Cohort Study. The rest of the samples were obtained from random blood
donors as whole blood.
b) De Villiers et al. (1999)
To determine the spectrum of sequence variants in the haemochromatosis (HFE)
gene, mutation analysis was performed on DNA of 965 individuals from four
different ethnic groups in South Africa. The sample was collected as whole
blood.
1.3.2 DNA Extraction
1.3.2.1 Chelex
a) Hamvas et al. (2001)
A 3 mm Guthrie card disc of each blood sample was heated in 2% Chelex in a 96
well microtiter plate format to extract the DNA.
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b) Olynyk et al. (1999)
DNA was extracted from the blood spots on the Guthrie cards using a Chelex
method as described by Singer-Sam and Tanguay (1989).
1.3.2.2 Whole Blood
a) Gaunt et al. (2001)
2 743 middle-aged Caucasoid males were screened for 11 markers across the
insulin-like growth factor 2 (/GF2) gene to determine if there is an association
between these single nucleotide polymorphisms and body mass index. The
samples used was attained from the NPHSII cohort, a set of previously collected
and extracted whole blood samples from nine widespread UK general practices.
The sample obtained form the NPHSII cohort was previously extracted from
whole blood using a standard lysis method.
b) Han et al. (2001)
DNA was previously extracted from whole blood by means of a standard lysis
method.
c) Pastinen et al. (2001)
The sample of 510 individuals obtained from the previous epidemiological
population-based study and the sample of 495 individuals from the Finnish Twin
Cohort Study were already extracted from whole blood, and the sample obtained
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from blood donors was extracted using a standard whole blood DNA extraction
protocol.
d) De Villiers et al. (1999)
Genomic DNA was extracted form whole blood using a standard lysis method
described by Miller et al. (1988).
1.3.2.3 Others
a) Todorava et al. (1999)
No DNA extraction was needed in this study, because PCR was done directly on
a disc of the Guthrie card.
1.3.3 Mutation Detection Methods
Various mutation detection methods were used in these studies, such as
restriction enzyme (RE) digestion, single strand conformational polymorphism
(SSCP) analysis and DNA-arrays. In some of these studies one method was
used to detect a mutation and another to confirm the result.
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1.3.3.1 Restriction Enzyme (RE) Digestion
a) Hamvas et al. (2001)
Restriction enzyme digestion with Styl was performed on the amplified DNA for
detection of mutation 121ins2 in the surfactant protein B gene.
b) Olynyk et al. (1999)
After PCR amplification of the area containing the gene in question, restriction-
enzyme digestion was used to identify the C282Y mutation in the HFE gene. If
the C282Y mutation was present, the individual was also screened for the H63D
mutation via restriction enzyme analysis.
1.3.3.2 Single Strand Conformation Polymorphism (SSCP) Analysis
a) Gaunt et al. (2001)
SSCP analysis of overlapping polymerase chain reaction (PCR) amplicons
spanning 200 - 250bp, as well as denaturing high performance liquid
chromatography (DHPLC) were performed to identify new SNP markers in the
IGF2 gene. Samples displaying a polymorphism were subsequently sequenced.
Known polymorphisms were detected by RE digestion or ARMS PCR
amplification (including an internal control), both of which were subsequently
electrophoresed in 96-well, 192-well or 384-well microplate array diagonal gel
electrophoresis (MADGE) gels as described by Gaunt et al. (2000).
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b) Todorava et al. (1999)
The sample was screened using SSCP analysis, and all heterozygote samples
found were digested with Rsal restriction enzyme to confirm the presence of the
C283Y mutation in the -y-SGgene.
c) De Villiers et al. (1999)
This population screening approach utilized a combined heteroduplex and single-
strand conformational polymorphism (HEX-SSCP). Where possible, restriction
enzyme analysis was performed to verify the sequence changes in PCR
amplified DNA, and for mutations not involving restriction enzyme recognition
sites, bi-directional sequencing was used.
1.3.3.3 Other
a) Han et al. (2001)
DHPLC was performed on a WAVE DNA analysis system by using a DNASep
system (Transgenomic). The DNASep columns contain non-porous alkylated
polystyrene-divinylbenzene particles that are both electrically neutral and
hydrophobic, thus the negatively charged phosphate ions of the DNA molecules
cannot bind to the column unaided. Triethylammonium acetate (TEM) is a
positively charged reagent that facilitates interaction between the stationary
matrix and the DNA molecules. By altering the ratio of TEM to acetonitrile, the
hydrophobic interaction between the alkyl chains of TEM and the stationary
phase of the column is reduced, thus allowing the DNA fragments to be eluted.
DNA molecules eluted from the column are detected by scanning with a UV-C
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detector. At a temperature that only partially denatures heteroduplexes, these
molecules are destabilized by the mismatched bases and are therefore slightly
more melted than the homoduplexes, resulting in earlier eluation.
Denaturing high performance liquid chromatography (DHPLC) is a modification of
the basic gel-based heteroduplex mutation analysis method. It relies upon the
rapid separation and visualization of homo- and heteroduplex DNA molecules by
using an ion-pair reverse-phase liquid chromatography system. The sensitivity of
the analysis is maximized by maintaining the HPLC column at a temperature that
favours partial strand denaturation in the presence of base-pair mismatching.
b) Pastinen et al. (2001)
DNA samples were screened by means of a DNA-array. This DNA-array was
constructed for detection of 31 common mutations in the Finnish population. A
pair of allele-specific primers for each of the mutations was spotted on
derivatized microscopic glass-slides. Eight replicated arrays were spotted onto
each slide. Custom-made reaction chambers were used to analyze up to 80
separate samples per slide, thus 2 480 mutations could be monitored on a single
microscopic glass-slide. Allele-specific primer extension reactions provided
reliable discrimination between the genotypes. The genotypes of carriers
identified by the array-based screening were confirmed using PCR-RFLP
digestion or allele-specific PCR with an internal control amplicon.
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1.4 Motivation for this study
According to Day (1986) an estimated 10000 - 20000 South African individuals
are carriers of the R59W mutation, and as many as 80% of these gene carriers
have not yet been diagnosed and are therefore at risk of potentially lethal acute
neurological attacks. However, during a study conducted at Tygerberg Hospital
(1997 - 1998), only 19.3% (81 /419) apparently unrelated South African patients
of European descent, referred for a DNA diagnosis of VP using RE analysis,
tested positive for the R59W mutation (De Villiers et al., unpublished results).
This relatively low detection rate of the R59W mutation among general referrals
is probably a consequence of inappropriate clinical and/or biochemical disease
assignment and emphasizes the pivotal role of genetic analysis in disorders
characterized by clinical features considered to be non-specific. Forty-two
patients previously diagnosed with VP based on biochemical testing of stool,
urine and blood tested negative for the founder mutation and were subsequently
screened for mutations in the promoter and coding region of PPOX using HEX-
SSCP analysis (Kotze et al., 1998). No disease-causing mutation could be
identified in these patients.
This poses a serious question regarding the actual frequency of VP, and
specifically the founder gene mutation, in South Africa. Seeing that the original
estimated frequency of VP in South Africa (Dean, 1960) was based on clinical
expression (known to be highly variable and unspecific) and biochemical tests
that are often inconclusive, the question arises whether there are thousands of
undiagnosed VP carriers, as genealogical studies and population growth curves
have predicted, or is the allele frequency much lower than the 0.3% which is still
widely cited in almost every publication on VP (e.g. Sassa, 2002; Von Und Zu
Fraunberg, 2002)?
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By re-estimating the frequency of the founder mutation using current rapid and
unequivocal DNA diagnostic tests, a more precise estimation can be made.
These results can be used to recommend appropriate genetic testing in the
future. If found that a large number of South Africans are unaware that they are
silent VP carriers, this finding will be publicized widely. By alerting both
physicians and individuals form the "at-risk" population groups, and underlining
the importance of accurate diagnosis, the risk of life-threatening acute attacks in
genetically susceptible individuals could be minimized. If, on the other hand, the
incidence of the R59W mutation is less than currently believed, it will also be
publicized to avoid inappropriate clinical or biochemical disease assignment
("overdiagnosis") in the future.
1.4.1 Aims of this study
This study had the following objectives:
1. To determine with greater preersion the frequency of the R59W founder
mutation among the Caucasian South African population.
2. To screen the population of mixed ancestry (Coloureds) and to determine the
frequency of the R59W founder mutation in this population. It has previously
been demonstrated that founder mutations in the LOL receptor gene provide
evidence of Caucasoid admixture and contribute significantly to the familial
hypercholesterolemia phenotype in the Coloured population (Loubser et al.,
1999).
3. To determine what percentage of the population are silent gene carriers and
unaware of their VP carrier status.
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To achieve these objectives, special techniques that are simple, rapid and
inexpensive had to be employed. In the words of Leung et al. (2001): "The ideal
high-throughput mutation screening method should be cheap, not requiring
expensive equipment with high running and maintenance cost, it should be simple,
no more complex than conventional electrophoresis, and it must be fast." To be
statistically meaningful, a large quantity of samples had to be screened. The
following specific aims were established:
1. Initial collection of 4 000 - 5 000 blood samples.
2. Development of information forms on VP for patients to read and take home.
3. Development of a shorter informed consent form. In order to collect a large
number of blood samples under special conditions (for example in maternity
wards) and to simplify the storage of these blood samples, it was necessary
to condense the lengthy informed consent form generally used. Other vital
information required with the sample was also acquired via this form.
4. Comparison of DNA collection and storage methods appropriate for the large
quantity of blood samples to be collected.
5. Comparison of rapid and cost-effective DNA isolation methods.
6. Employment of a simple and inexpensive method for detecting the R59W
mutation.
7. Development of a database to record individual samples collected and tested.
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2. 1 Ethical Approval
Ethical approval for this study was given by the Ethical Committee of the Faculty
of Health Sciences, University of Stellenbosch. The study was also approved by
the Tygerboland Onafhanklike GinekologieseAssosiasie (TOGA), the Medi-Clinic
group, the Netcare group, PathCare, Ampath, Lancet Laboratories, and the
South African Blood Transfusion Services.
2.2 The Study Populations
The VP gene frequency of 0.3% was initially described in the Caucasoid
population of European decent (Dean, 1960), and for comparison purposes, the
current study had to use this population as well. Areas with a high concentration
of especially Afrikaans-speaking Caucasians were focused on, and for control
purposes, at least three geographical areas within South Africa (Western Cape,
Gauteng and the Free State) were included. People of mixed ancestry
(Coloureds) were also included, however, no persons wanting to participate in
the study were excluded on grounds of language preference or race.
Collaboration with the South African Blood Transfusion Services, various
pathology laboratories and maternity units of hospitals were established and
obstetricians, hospital administrators and other personnel at these various
organizations were visited to inform them of the project and to discuss possible
logistic problems. They were asked to encourage white Afrikaans speaking and
Coloured patients to participate. Information forms, informed consent forms and
either Guthrie cards (Schleicher and Schuell) or FTA cards (Whatman
BioScience) were distributed. Information such as the home language of the
family, race and VP status of the parents and the extended family were recorded.
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All sampleswere obtained anonymously, except in cases where the donor (or the
parents of newborns) wished to know the result of the test. In these cases
names and addresses of the patients and their physicians were recorded.
2.2.1 Blood Donor Clinics
A total of 2 380 samples were obtained by attending the Blood Transfusion
Services clinics in the Western Province, Free State and Gauteng. Blood donors
were informed about the project and asked to participate. After the donor
completed the informed consent form, some of the excess blood from the finger
prick (used for testing blood Fe levels) was spotted on a Guthrie card. The card
was allowed to dry (10 - 15 min) and stored in a cool, dry place until DNA
extraction could be performed.
Samples obtained from clinics attendedwere immediately collected, and samples
obtained from clinics in Gauteng and the Free State, after the initial three-week
personal attendance, were posted to Stellenbosch by the clinic personnel at
regular intervals. Samples in the Western Cape were collected between June
2000 and December 2001 and samples in Gauteng and the Free State were
collected from February 2002 until May 2002.
2.2.2 Pathology Clinics
Pathology clinics in the Western Cape (PathCare), the Free State (PathCare)
and Gauteng (Lancet Laboratories and Ampath) were asked to participate in
collection of the 853 samples from patients referred for a routine test, such as an
HIV test. Personnel asked the patients for their participation. An EDTA tube of
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blood was drawn from willing participants, and the blood was stored at 4°C until
the samples were collected. Western Cape samples were collected fortnightly
and samples from the Free State and Gauteng were sent to us within two weeks
of collection. All samples were spotted onto Guthrie or FTA cards at the
laboratory in Stellenbosch, except for samples obtained from Lancet Laboratories
(Gauteng), which were spotted on Guthrie cards before it was sent to
Stellenbosch. These samples were sent to us at regular intervals, usually in
batches of 100. During our initial visit to clinics in Gauteng and the Free State,
samples obtained at the various pathology clinics were spotted and collected
within a week after it was obtained.
Samples obtained from pathology clinics in the Western Cape were collected
from November 2000 until May 2002 and samples form clinics in Gauteng and
the Free State were collected form March 2002 until May 2002.
2.2.3 Maternity Wards
Maternity wards of hospitals in the Western Cape participated in the collection of
umbilical cord blood samples from 839 newborn babies. Stellenbosch Medi-
Clinic (MC), Somerset-West MC, Durbanville MC, Paarl MC, Worcester MC,
Milnerton MC, Panorama MC, Louis Leipoldt MC, N1 City (Netcare) and
Tygerberg hospital (Provincial Administrator of the Western Cape) participated in
this part of the sample collection. The neonatal ward personnel or the
obstetrician, before labour, obtained informed consent from the mother, and
some of the blood present in the umbilical cord was spotted on a Guthrie card.
The samples were collected fortnightly from the maternity wards from November
2000 until May 2002.
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2.3 DNA Isolation
2.3.1 Chelex
Four discs were removed from a sample on a Guthrie card (Schleicher and
Schuell) using a 1.2 mm punch (Whatman BioScience), and inserted into a sterile
1.5,u1 microfuge tube. 600!l1 TE-buffer (0.1 M TRIS HCI, pH 7.6 and 0.01 M
EDTA, pH 8.0) was added to the discs before the contents of the microfuge tube
was incubated at room temperature for an hour and occasionally mixed by
inversion. Subsequently the microfuge tube was centrifuged for 3 min at 13 500
rpm (16 200 x g) and the supernatant carefully poured off, leaving -30,u1 of TE-
buffer and the discs behind. Another 600 ,uI TE-buffer was added to the
microfuge tube. The microfuge tube was inverted occasionally while incubated at
room temperature for 10 min before it was centrifuged at 13000 rpm (16 200 x g)
for 3 min. All but -30,u1 of the supernatant was removed and 200,u1 of 10% (10
g / 100 ml H20) Chelex was added to the pellet. As EDTA is a PCR inhibitor and
Chelex is rich in EDTA, the Chelex working stock was washed before being used
by removing as much water from the Chelex stock as possible without loosing
any beads and replacing it with sdH20. The microfuge tube was then incubated
in a water bath at 56°C (±2 °C) for 30 min, where after it was vortexed for 10 sec
and centrifuged at 13 500 rpm (16 200 x g) for 20 sec. It was then incubated at
100°C (±2 °C) for 8 min in a heating block. The lid of the microfuge tube was
punctured to prevent it from popping open at this high temperature.
The tube was centrifuged at 13 500 rpm (16 200 x g) for 3 min and subsequently
the supernatant contained the DNA, which was now ready to be used as
template in a subsequent manipulation. The DNA was stored at 4 "C and used
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within 48 hours after extraction. Care was taken not to carry any Chelex beads
over when the DNAwas used.
2.3.2 FTA Purification Solution
A clean 1.2 mm punch was used to remove one disc from the middle of the
bloodstain on the FTA card (Whatman BioScience) and to place it into a sterile
200 pi microfuge tube. 100 Jil FTA purification solution (Whatman BioScience)
was added to the disc and vortexed at slow speed for 2 sec, followed by a 5 min
incubation at room temperature with another 2 sec low speed vortex halfway
through and at completion of the incubation. As much of the FTA solution as
possible was removed with a pipette. Another 100 Jil FTA purification solution
was added to the tube and the above procedure repeated. After a third wash
cycle, 100 pi TE-buffer was pipetted into the amplification tube to rinse off any
residual FTA purification solution still present. After a 5 min incubation at room
temperature, with brief vortexing halfway and at completion, as much of the TE-
buffer as possible was removed. The FTA card disc was used in subsequent
PCR reactions.
2.3.3 Whole Blood extraction
Whole blood extraction was performed according to a protocol by Miller et al.
(1988). 5 ml whole blood was placed in a 50 ml Falcon tube and 30ml of cold
lysis buffer (0.155 M NH4CI, 0.01 M KHC03, 0.0001 M EDTA, pH 7.4) was
added. The tube was placed on ice for 15 min and shaken every 5 min.
Subsequently it was centrifuged for 10 min at 1 500 rpm (201 x g). The
supernatant was removed and the pellet washed with 10 ml PBS (0.027 M KCI,
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0.137 M NaCI, 0.008 M Na2HP04, 0.0015 M KH2P04). The Falcon tube was
centrifuged at 1 500 rpm (201 x g) for another 10 min before the supernatant was
carefully removed and discarded. The pellet was dissolved in 3 ml nuclei lyses
solution (0.01 M Tris HCI, 0.4 M NaCI, 0.002 M EDTA, pH 8.2), 10 mg/ml
protease K (Roche) and 300 Jl110% SOS (w/v), and incubated at 55°C overnight.
The next morning 1 ml 6M NaCI was added and the Falcon tube was shaken
vigorously for 1 min and subsequently centrifuged at 2 500 rpm (559 x g) for 15
min. The supernatant was transferred to a new Falcon tube, taking care not to
carry over any of the pellet or foam. Two volumes of 100% EtOH (v/v) were
added to precipitate the DNA. The DNA was transferred to a 1.5 ml microfuge
tube, 1 ml 70% EtOH was added and the tube was centrifuged at 13 500 rpm
(16 300 x g) for 5 min. The supernatant was subsequently removed and the
microfuge tube was left uncapped for 10 min to allow the EtOH to evaporate.
Depending on the size of the pellet, 200 - 800 JlI dH20 was added, and the DNA
was resuspended by placing it on a shaker at low speed for an hour. The DNA
was subsequently stored at -20°C.
2.4 peR amplification
Amplification of the R59W mutation region via the polymerase chain reaction
(PCR) was performed to acquire adequate quantities of DNA to perform the
different mutation detection techniques. Various primer combinations were
utilized in order to obtain fragments best suited for subsequent mutation
detection via ARMS, RE analysis and SSCP analysis. These primers are listed
in Table 2.1, and their positions indicated on the relevant portion of the PPOX
sequence in Table 2.2.
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Special care was taken to prevent contamination of samples before PCR
amplification. All the pipettes used were regularly sterilized soaking it in a 20%
liquid bleach solution for 20 min. The pipettes were also sterilized by placing it
under UV light in a Biocap (Erlab) cabinet for 15 min prior to usage. All pipetting
was performed with filter tips, and a positive and negative control reaction was
always included in every group of simultaneous amplification reactions. Only a
small quantity of primer working solution was prepared at one time, and aliquots
of each working solution were made.
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Table 2.1: Summary of primers used in this study
Primer Reference
Primer sequence Tm
name
Warnich et al.,
PP02F 5'- -3' 73
1996(b)
"C
Warnich et al.,
"- PP03F 5'- 3' 55.6ns 1996(b)!
0
u, Warnich,
SF 5'- -3' 51.4
unpublished
Warnich et al.,
PP010F 5'- - 3' 81
1996(b)
Warnich et al.,
PP03R 5' - GCT CCC CTA AAC TCT ATT CC - 3' 52.2
1996(b)
Warnich et al.,
PP04R 5' - GAG GGC ACA GTA AM GGA ~C - 3' 56.6
1996(b)
PPOXAR 5' - G~Q TG~ QQT AAT TQA QCA - 3' 69
This study
Cl)
I/)
"-
Cl)
> This studyCl)0:: PP03AR 5' - GCT ~GC QTA ATT QCQ QG - 3' 47
Warnich et al.,
PP010R 5' - TGG CCT TGC CTA CAA TGG AGC AC - 3' 81
1996(b)
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Table 2.2: Primer annealing positions indicated on the PPOX sequence. (T) = R59W
mutation, a C to T transition.
961 ccaccagccc atccgtgcac acttagtttc ccctaaagca gtgagtggcc gggatagaac
1021 tcaaaaccgg cgg tctgcctgtc catatcgccc
1081 cctttccccc aggtttccgc atgggccgga ccgtggtcgt gctgggcgga ggcatcagcg
1141 gcttggccgc cagttaccac ctgagccggg ccccctgccc ccctaaggtg agtgctccac
1201 ttgtgccaga gggagcttca tttaatgctc ttcccatttc catcaaaagc tagatggatc
1261 ctggccctct gaatatgcct cttacccctc cctactgacc tctcggcggc ggctacaggc
1321 9 agcgt
1381 ctgggaggct ggattcgctc cgttcgaggc cctaatggtg ctatctttga gcttggacct
1441 (Tlggggaatta ggccagcgggagccctaggg gcccggacct tgctcctggt gagaggcttg
1501 tgggatgtct aggagaggtt gtggaggggg cttccattgg ggaatagagt ttaggggagg
1561 aagtatgttt ggtgggtcag atcttccctt agtttctcct cttctgaggg catgtggaga
1621 gcaggtttct gagcttggct tggattcaga agtgctgcct gtccggggag accacccagc
1681 tgcccagaac aggttcctct acgtgggcgg tgccctgcat gccctaccca ctggcctcag
1741 gtaacaccag cacctccgct ccttttactg tgccctcatc ctcatatgcc ttccatttct
4321 tgtaatccca gcattttggg aggccgaggt gggcagataa caaggtcagg agttcgagac
4381 cagcctggcc aacatggtga aaccccatct ctatgaaaaa tacaaaaatt agccaggtgt
4441 ggtggcttgc acctgtaatc tcagctactc gggaggctaa ggcaggagaa tcgcttgaac
4501 ccaggaggtg gaggttgcag tgagctgaga tctcgccatt acactccagc ctgggtgaca
4561 gagtgagact ctgtcccccc caccccccca aaaaaatggg aaggagagac agcctcagct
4621 cttctctcca gggatttgga catttggtgc
4681 catcttcaga agatccagga gtcctgggaa tcgtgtatga ctcagttgct ttccctgagc
4741 aggacgggag cccccctggc ctcagagtga ctgtgaggag gaggaaactt tgcctagtgg
4801 catttccaga gggctcctct gtgctccatt gtaggcaagg ccagactgat cagtgctata
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peR primer stock solutions of 100 pmol/pl were diluted to 15 pmol/pl working
solutions. The following peR program was used for DNA amplification in a
GeneAmp peR System 9 700 peR cycler (Applied Biosystems)(Table 2.3).
Table 2.3: peR program used for amplification of DNA
peR step Description tof cycles Temperature Duration
1 Denaturation 1 95 7min
2 Denaturation 95 30sec
Annealing 1 0-10 55-65 30sec
Extension 72 30sec
3 Denaturation 95 30sec
Annealing 2 30 - 40 55-60 30sec
Extension 72 30sec
4 Extension 1 72 7min
Mgel2 concentrations of between 0.5 mM and 2.5 mM were tested. The total
reaction volume for all reactions was 25 pi, unless stated otherwise. peR
reactions were performed in either 200 pi microfuge tubes or microtiter plates.
The peR mixture for optimal amplification using the PP02F and PP04R primer
pair contained the following: 1x peR buffer (Bioline), 1.0 mM Mgel2, 200 pM of
each dNTP [2'-deoxyadenosine-5'triphosphate (dATP), 2'-deoxycytidine-
5'triphosphate (deTP), 2'-deoxyguanosine-5'triphosphate (dGTP) and 2'-
deoxythymidine-5'-triphosphate (dTTP)], 0.32 mM of each of the PP02F and
.PP04R primers, 1 U Bioline Biotaq DNA polymerase and 1pl gDNA extracted
from whole blood or Guthrie cards. The peR program used for optimum
amplification is shown in Table 2.3, with annealing temperature one as 62°e (10
cycles) and annealing temperature two as 5re (40 cycles).
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The PCR mixture for optimal amplification using the PP03F and PP03R primer
pair contained the following: 1x PCR buffer, 0.75 mM MgCI2, 250 pM of each
dNTP, 0.75 mM of the each of the PP03F and PP03R primers, 1 U Bioline
Biotaq DNA polymerase and 1pi Chelex extracted DNA or the disc prepared for
PCR with FTA purification reagent. A reaction volume of 20 pi was found to be
sufficient for SSCP analysis. Annealing temperatures of 64°C (10 cycles) and
60°C (30 cycles) provided the best amplification.
For optimum amplification with the PP03F and PP04R primer pair, the following
reagent concentrations were used: 1x PCR buffer, 1.0 mM MgCI2, 200 pM of
each dNTP, 0.6 mM of the each of the PP03F and PP03R primers, 1 U Bioline
Biotaq DNA polymerase and 1pi Chelex extracted DNA or the disc prepared for
PCR with FTA purification reagent. A reaction volume of 50 pi was initially used,
but was later downscaled to 25 pI. A PCR annealing temperature of 64°C for
cycle one (10 cycles) and 59°C for cycle two (30 cycles) were used.
2.5 Mutation Detection Methods
2.5.1 Restriction enzyme (RE) analysis
PCR for RE analysis was performed on whole blood and Chelex extracted DNA,
with the PP02F and PP04R or the PP03F and PP04R primer pairs.
The PCR product of both the PP02F and PP04R and PP03F and PP04R
primer pairs were cut with Styl by adding 5 U (0.5 pi) Styl (Roche), 2 pi buffer
(Roche) and 7.5pl H20 to 10pl amplified DNA and incubating the mixture
overnight at 3rC. The digested fragments were separated on a 20 ml 12% PM
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gel (6 ml 40% poly-acrylamide, 6 ml 5x TBE and 4 ml H20, polymerized with 50
pi APS (25% w/v) and 20 pi TEMED). 5 pi loading buffer (0.25% w/v
Bromophenol Blue in dH20) was added to 10 pi of the digested DNA and loaded
onto the gel. The gel was run at 200 V for 1.5 h and visualized under UV light
subsequent to EtBr staining.
2.5.2 Single Strand Conformation Polymorphism (SSCP) analysis
2.5.2.1 SSCP Procedure
The PCR product of the PP03F and PP03R primers, of either Chelex or FTA
purification reagent extracted DNA, was used for SSCP analysis.
DNA amplified for SSCP analysis was run on 20% poly-acrylamide (PAA) gels
(99 acrylamide: 1 bis-acrylamide, 1% cross linking). 5 ml 40% PAA stock, 3 ml
5x TBE and 2 ml H20, polymerized with 1.33 pi 10% APS (w/v) and 13.3 pi
TEMED, were used for one Mighty Small (Hoefer Scientific Instruments) SSCP
gel. Ten samples were loaded per gel in 1.5x TBE buffer.
6 pi 80% (w/v) formamide loading buffer was added to 14 pi PCR product. The
sample was then denatured by keeping it at 9rC for 7 min in a PCR cycler and
was subsequently placed on ice to keep it denatured until it could be loaded onto
the gel. 3.5 pi of a sample was loaded per well, and the gel was run at 200 V for
2.5 hours. The fragments were subsequently visualized by silver staining.
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2.5.2.2 Silver Staining
The gel was covered with a fixing solution (10% (v/v) EtOH, 0.5% (v/v) acetic
acid) for 10 min and placed on a belly dancer (Stovall Life Science, Inc.) at low
speed, where after the fixing solution was discarded and the gel was rinsed twice
by covering it with ddH20 and placing it on the belly dancer for 1 min. The gel
was then stained by covering it with a solution of 0.1% (w/v) AgN03 and shaking
it on the belly dancer for a minimum of 10 min. The staining solution was
discarded into a marked container for proper detoxification and the gel was
rinsed by covering it with H20 and shaking it for 5 sec. The gel was covered with
1.5% (w/v) NaOH solution to which 0.405% (v/v) formaldehyde was added just
before use, as a developing solution. The developing solution was discarded into
a marked container as soon as any bands became visible on the gel (after - 6
min), and the gel was rinsed at least 3 times with H20 to prevent further
development. The water used for rinsing was also discarded into the marked
container and the gels were sealed between transparencies for storage.
2.5.3 The Amplification Refractory Mutation System (ARMS)
ARMS utilizes a primer designed to anneal to gDNA only if a specific mutation is
present (or absent) (Newton et ai., 1989). Two ARMS primers, both with their 3'
nucleotide (critical for amplification) on the C to T transition of the R59W
mutation, were designed using the program "Primer" 5.0. An ARMS primer was
used as a nested primer or in conjunction with another primer pair, so that an
internal control for successful amplification was always present.
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PP03AR was designed to anneal to PPOX if the R59W mutation is present. This
primer was tested in conjunction with PP02F and PP03R as a nested primer,
with PCR reagents as follows: 1x PCR buffer, 1.5 mM MgCI2,200 JIM of each
dNTP, 0.5 mM of each of the 3 primers, 1 U Sioline Siotaq DNA polymerase and
1 pi gDNA (extracted from whole blood). The PCR program as described in
Table 2.3 was used, and best amplification was obtained with annealing
temperatures of 64°C (10 cycles) and 61°C (40 cycles).
PPOXAR was based on PPOX3R and also designed to anneal to gDNA if the
R59W mutation is present. To increase the annealing stringency of this primer,
the fourth nucleotide from the 5' side was changed from a cytosine to an
adenine, creating a deliberate mismatch, as suggested by Newton et al., 1989.
PPOXAR was used as a nested primer in conjunction with PP02F and PP03R
primers with PCR reagent concentrations as described in the previous
paragraph, and annealing temperatures of 64°C (10 cycles) and 59°C (40 cycles)
yielded the best amplification.
The PPOXAR primer was also used as a nested primer in conjunction with the
SF and PP03R primers, with the following PCR reagent concentrations: 1x PCR
buffer, 1.5 mM MgCI2,50 JIM of each dNTP, 0.5 mM of the each of the 3 pimers,
1 U Sioline Siotaq DNA polymerase and 1pi gDNA. The best amplification was
obtained with annealing temperatures of 64°C (10 cycles) and 61°C (40 cycles).
PPOXAR, together with the PP02F forward primer, was also used in conjunction
with the PP010F and PP010R primer pair. The PCR reaction mixture yielding
the best result was as follows: 1x PCR buffer, 1.5 mM MgCb, 200 JIM of each
dNTP, 3mM of the each of the PPOXAR and PP02F primers, and 1.5 mM of
each of the PP010F and PP010R primers, 1 U Sioline Siotaq DNA polymerase
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and 1pl of Chelex extracted DNA. Optimum amplification was obtained with
annealing temperatures of 65°C (10 cycles) and 62°C (40 cycles).
Amplification products were detected on a 1.5% agarose gel, with EtBr, under UV
light.
2.6 Database Design
A database for collection of the information obtained from the informed consent
forms were designed using Microsoft Excel, and updated regularly. The result of
each sample's R59W mutation test was also added to the database.
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3.1 Development of Information Form
Information forms in Afrikaans (Appendix A) and English (Appendix B) were
developed to inform potential sample donors in easily understandable terms what
variegate porphyria (VP) is, why the incidence of the disease is so high in South
Africa, what the symptoms associated with VP are and what the aims of the
study are. The potential donor was also informed that the blood sample donated
would only be used for the VP research project and that the results of his or her
test for the founder mutation VP would be disclosed to him/her via their
physician, if so desired. The form could be taken home and contains contact
details if the donor requires any additional information.
3.2 Development of Informed Consent Form
A shorter, more compact informed consent form (compared to the three to seven
page copy that is usually used in genetic studies) in Afrikaans (Appendix C) and
English (Appendix D) were developed to simplify the filling in of the form,
(especially for use in maternity wards where the regularly used extended form
would have been unfeasible). The Guthrie or FTA cards were attached to the
forms and the subsequent storage of the form together with the sample was thus
also simplified. Information vital to the project, such as the patient's gender,
race, home language, age group and known inherited diseases were also
recorded on this form.
Anonymous samples did not require informed consent, but if the patient chose to
be notified regarding the result of the test, his/her name, address and telephone
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number as well as the name, address and telephone number of his/her doctor
were required, and informed consent had to be signed.
3.3 Development of a Database for Samples Collected
Information obtained from the informed consent form was entered into a
Microsoft Excel database. The name of the hospital or clinic where each sample
was obtained was also added to the database to simplify finding a specific
sample in case of a query and to compare the number of samples obtained from
each hospital of clinic. The result of each R59W mutation test was also added to
the database.
3.4 Collection of Samples
3.4.1 Samples Collected
From June 2000 to May 2002 a total of 4 072 samples were collected from blood
transfusion clinics, pathology clinics and maternity wards in the Western Cape,
and from blood transfusion clinics and pathology clinics in Gauteng and the Free
State. The number of samples obtained from the three geographical areas as
well as the different main collection points are listed in Table 3.1.
Table 3.1: Summary of total number of samples collected
Western Cape Gauteng Free State Total
Blood Transfusion Clinics 1879 420 81 2380
Pathology Clinics 437 327 89 853
Maternity Wards 839 0 0 839
Total 3155 747 170 4072
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As collection of samples initially started in the Western Cape in June 2000 and
only by March 2002 in Gauteng and the Free State, the majority of the samples
were obtained from the Western Cape.
Table 3.2 depicts the gender, language and race distribution of the samples
obtained from the three provinces. The race distribution of the study population
is also depicted in Figure 3.1. As the previous frequency determination of the
R59W mutation in South Africa was done on a Caucasian population and the
descendants of the founder couple was to be mainly from the Afrikaner
population, areas with a high concentration of Afrikaans-speaking Caucasians
were targeted, such as the Northern suburbs of Cape Town. Seventy-nine
percent (3 233) of the total sample population were White South Africans, 17%
(692) were of mixed ancestry (Coloureds) and 2% (79) were black patients. Of
the White South Africans, 78% (2 544) were Afrikaans-speaking, thus 62% of the
total study populationwas Afrikaners.
Figure 3.1: Racial distribution of the total study population.
Ill! Caucasian
• Coloured
o Black
DOther
2%
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Table 3.2: Sample population in terms of gender, language and racial distribution
Language
English
Blood Transfusion Services 1353 505 21
Westem Pathology Clinics 370 65 2
Cape Newborn Babies 638 156 45
Subtotal 2361 726 68
~
-....J Blood Transfusion Services 273 133 14
Gauteng Pathology Clinics 301 25
Subtotal 574 158 15
Blood Transfusion Services 68 13 0
Free State Pathology Clinics 5 2
::0
Subtotal 18 2 (1)CJ)
c::
TOTAL 3085 902 85 ;::+CJ)
Il)
:::Ja.
CJ00·
0
c::
CJ)
CJ)
0"
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3.4.2 Problems Experienced with Collection of Samples
Even though posters were put up at participating collection points and
information and informed consent forms for this project were placed at the most
practical and observable positions at the collection points, minimal public
participation was obtained when potential donors were not approached and
asked for their participation.
Sample collection at any specific blood donation clinic could only be performed
for a period of three months. This was to prevent possible double collection of
samples, because individuals may donate blood every three months. This
implies that collection of blood samples from the donors at any specific clinic had
to be as effective as possible within that period. The collection of these blood
samples cause more work for the clinic staff, not only for the physical collection
of the sample, but also to approach potential sample donors for their
participation. The blood transfusion clinics are generally understaffed, not
allowing for a staff member to help blood donors fill out forms and to ask the
donor to participate in the founder mutation screening project. Only a few donors
participated in the project when the information and informed consent forms were
placed with the forms of the blood transfusion services, without approaching
them for participation. Personal attendance, although very time consuming,
proved to be at least four times as effective in the collection of samples from this
source.
Blood samples from the umbilical cords of newborn babies had to be obtained by
the nursing staff in the maternity ward. It is understandable that the collection of
these samples would have the lowest priority when a baby is born. Initially we
attempted to distribute information and informed consent forms to the
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obstetricians involved at the various hospitals' maternity wards, so that the
informed consent form could be completed before delivery of the baby. This
approach was unsuccessful, as too many obstetricians were involved to make it
practically feasible. Frequent visits to the maternity wards of the participating
hospitals were necessary to call on the nursing staff's renewed enthusiasm in the
collection of samples for this project.
The rate of sample collection at pathology clinics was very slow. This was
largely due to the large number of patients visiting these clinics, not allowing too
much time to be spent per patient by the personnel, and also because an extra
blood sample in an EDTA tube had to be collected from sample donors.
3.5 DNA Isolation
3.5.1 Whole Blood DNA Isolation
A total of 56 whole blood DNA isolations were performed. This procedure had to
be performed over a period of two days, and the number of samples that could
be done at once was limited by the large size of the Falcon tubes - only four
tubes could be centrifuge simultaneously in the Beckman CS15R centrifuge,
used in our laboratory, for each of the 10 min centrifugation steps.
Even though the procedure is time consuming, whole blood extraction yields 200
- BOO pi of high concentration DNA. As 1 IJl of DNA is adequate per PCR, this
DNA can be used for numerous reactions. The DNA can also be stored at -BO°C
for years without degradation, as long as it is not defrosted and refrozen too
often. However, for the purposes of this study, where samples are only screened
once and subsequent PCR amplification was only done if a R59W mutation was
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detected or if the initial amplification was unsuccessful, the high quantity of DNA
isolated is unnecessary, thus not justifying the extraction time or the high cost of
this procedure.
3.5.2 Chelex DNA Isolation
The DNA of all samples obtained on Guthrie cards and most of the samples
obtained as whole blood (subsequently spotted out on Guthrie cards), were
isolated using Chelex. The isolation procedure was found not to be very labour
intensive or time consuming and the DNA from 48 samples could be isolated in
1.5 h. Twenty four samples could be centrifuged at one time in the Beckman
CS15R centrifuge used in our laboratory, thus not prolonging the extraction
procedure too much. The quality of the isolated DNA was adequate for PCR
amplification, though the concentration was too low to be determined by either
photospectrometry or gel electrophoresis. Approximately 200 pi DNA was
available subsequent to Chelex extraction.
The Chelex beads are rich in EDTA (a known PCR inhibitor) and the supernatant
containing the DNA should be removed and placed into a new microfuge tube for
storage. As these samples were only reused if a sample was positive for the
R59W mutation or if the initial PCR amplification was unsuccessful, the DNA
could be used directly from the microfuge tube that was used for the extraction,
thus saving the cost of a set of storage tubes. We found that DNA left in the
container with Chelex beads and kept at 4°C could be used for successful PCR
amplification up to 2 weeks after extraction.
In a study done by Hamvas et al. (2001), where 10 044 samples obtained on
Guthrie cards and DNA isolation was performed with Chelex, it was reported that
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99.2% of the PCR amplifications were successful on the first attempt, and that a
successful Chelex extraction was performed on a 6 year old Guthrie card
sample. We found an equally high PCR success rate with DNA isolated from
Guthrie cards with Chelex. Because DNA can still be successfully isolated from
Guthrie cards after such a long time, it is very favourable when compared to DNA
isolation from whole blood, which must be performed within 2 weeks after the
sample has been obtained if stored at 4°C, and somewhat longer if stored at -
20°C. Storage of large quantities of whole blood samples took up a lot of space
in these cooling facilities, further adding to the appeal of sample collection on
cards.
The Guthrie cards were stored at room temperature, away from dampness and
direct sunlight.
3.5.3 FTA Purification Solution DNA Isolation
The DNA from samples obtained on FTA cards was isolated using FTA
Purification Solution. This isolation method proved to be fast (one hour for 96
samples) and not labour intensive. No centrifugation was needed and
amplification was performed directly on the FTA card disc in the same tube used
for the DNA isolation, making the use of microtiter plates ideal. Only one 1.3 mm
disc of the blood spotted FTA card was used per PCR, so ample DNA was
available on the card for subsequent PCR amplification, if this was found
necessary.
The FTA cards were stored at room temperature, away from dampness and
direct sunlight.
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3.5.4 Comparison of DNA Isolation Methods
As this project only required DNA from each sample to be used once of twice,
whole blood DNA isolation proved to be too expensive and too time consuming.
If one compares FTA purification solution DNA isolation from FTA cards to that of
Chelex DNA isolation done on Guthrie cards, the FTA method is more expensive,
but the DNA can be isolated in a microtiter plate and subsequently PCR amplified
in the same microtiter plate, saving time and costs. DNA isolation and
amplification in microtiter plate format also lends itself towards automation for
DNA-array based mutation detection (see 1.3.3.3(b)). DNA can also be stored
on FTA cards for over 11 years without any loss in PCR efficiency
(www.dnatestingcentre.com/FTA_cards.htm).
McCabe et al. (1999) as well as Todorova et al. (1999) report successful direct
amplification of DNA on Guthrie card discs with no prior DNA isolation required.
Our attempts at direct PCR amplification of DNA on Guthrie cards were
unfortunately unsuccessful. Substantial savings on time and costs could have
been achieved if the Chelex DNA isolation procedure could be omitted before
PCR amplification of the samples.
3.6 Mutation Detection Systems
3.6.1 Amplification Refractory Mutation System (ARMS)
The ARMS primer PP03AR, in conjunction with the PP02F primer, failed to
distinguish between samples with and without the R59W mutation. At lower
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annealing temperatures the primer annealed to gDNA, regardless of the
presence or absence of the single base mutation, and at higher annealing
temperatures it failed to anneal to the gDNA.
PPOXAR, the ARMS primer designed with a deliberate mismatch at the fourth
nucleotide from the 3' side, to increase annealing stringency (Newton et al.,
1989), was used as a nested primer in conjunction with the PP02F and PP03R
primers to screen for the R59W mutation. After PCR amplification, the DNA was
run on a 1.5% agarose gel. The nested ARMS primer was able to detect the
R59W mutation, but amplification of the fragment between the flanking primers
was primarily obtained, with little amplification of the fragment between the
PP02F and PPOXAR primers. PPOXAR was also used in conjunction with the
SF and PP03R primer pair, and amplification between the flanking primers were
also primarily obtained, with little or no amplification of the region between SF
and PPOXAR.
The best results were obtained by multiplexing, using PP02F and PPOXAR in
conjunction with the PP010F and PP010R primers, the latter pair serving as an
amplification control (see Figure 3.2).
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Figure 3.2: ARMS primer PPOXAR and PP02F in conjunction with PP010F and PP010R primer.
PPOXAR and PP02F only amplify the 420 bp fragment if the R59W mutation is present. L
= a 100 bp ladder. In samples 1 - 7 the R59W mutation is absent, while the mutation is
present in sample 8. N = a negative PCR control.
500 bp
300 bp - -
Primer dimers
--+- 420bp
223 bp
The 223 bp amplicon of the PP010F and PP010R primer pair was present in all
successful PCR reactions, and the 420 bp amplicon of the PP02F and PPOXAR
primer pair was only obtained if the R59W mutation was present in a sample. A
high quantity of primer dimers was unfortunately obtained at conditions optimized
for PP02F and PPOXAR amplicon amplification.
One thousand and forty-one samples from the Western Province Blood
Transfusion Services were screened using PPOXAR and PP02F, together with
PP010F and PP010R as a control for successful amplification. PCR
amplification was done in microtiter plate format on DNA isolated from Guthrie
cards with Chelex. One sample was found positive for the R59W mutation. A
subsequent DNA isolation and PCR amplification was performed before digested
with Styl restriction enzyme to confirm the presence of the mutation.
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Even though this primer combination could be used to detect the R59W mutation,
it was often difficult to differentiate between R59W positive and negative
samples, because non-specific annealing of the ARMS primer and subsequent
amplification of the test fragment (between PPOXAR and PP02F) were often
obtained. Thus, to confirm results obtained with the ARMS test, all these
samples were re-extracted and retested using restriction enzyme digestion.
In a study performed by Waterfall and Cobb (2001) two ARMS primers were
used in conjunction with two flanking primers in a multiplex reaction to determine
the zygosity of patients for sickle cell anaemia. As individuals can be
homozygous (HbSIS), heterozygous carriers (HbAlS) or normal (HbAlA), two
separate ARMS PCR reactions, one for HbA and one for HBS, were previously
needed to screen for this disease. The authors report difficulty optimizing the
four primer reaction, but successful distinction between the three genotypes was
obtained using HotStart Taq DNA polymerase. When this very expensive Taq
DNA polymerase (Roche) was used, amplification of the large fragment between
the flanking primers was not always obtained. Because the PCR product of at
least one of the two ARMS primers must always be present (serving as a control
for successful amplification), amplification of the fragment between the two
flanking primers is not necessary in this case. As experienced in the R59W
mutation screening study, the authors also found that amplification of the large
fragment was generally done at the expense of the allele-specific fragment, with
subsequent decreased specificity. PCR amplification using Amplitaq Gold
(Applied Biosystems) yielded improved results, but the high cost made the use of
this enzyme unfeasible.
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3.6.2 Restriction Enzyme Digestion
Restriction enzyme (RE) digestion with Styl was performed on 1 041 samples
obtained form the Western Cape Blood Transfusion clinics and 378 samples
obtained from newborn babies in the Western Cape. No R59W positive samples,
other than the one previously detected with ARMS, were found in the group of
1 041 samples previously tested. None of the 378 samples obtained from
newborn babies in the Western Cape were mutation-positive.
Figure 3.3: Restriction enzyme digestion with Styl on amplification product of PP02F and PP04R.
The R59Wmutation is absent in sample 1 - 5, and present in sample 6.
434 bp
313 bp
287 bp
RE digestion of the PCR product obtained with primers PP02F and PP04R
always yielded two fragments, one of 434 bp and one of 313 bp. This served as
an internal control for successful RE digestion. When the R59W mutation was
present, another RE digestion site was created, 26 bp from the 3' end of the 313
bp fragment, thus yielding a third (287 bp) and fourth (26 bp) fragment. Because
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the 26 bp fragment migrated rapidly through the 12% PAA gel, this fragment was
not visible on the gel after EtBr staining, thus a 434, a 287 and a 313 bp fragment
were obtained after digestion of a heterozygous R59W sample.
3.6.3 Single Strand Conformation Polymorphism (SSCP) Analysis
The presence of the R59W mutation causes a conformational change in the PCR
amplified DNA. If the amplified fragment is short, (less than 400 bp) this
conformational change can be detected by denaturing the double stranded DNA
to yield single strands, and running it on a high density gel, as the conformational
change affects the migration tempo of the single strand DNA. After PCR
amplification with the PP03F and PP03R primer pair, SSCP analysis was
performed on the majority of the samples, i.e. 1 339 samples obtained from the
blood transfusion clinics, 853 samples obtained from pathology clinics and 461
samples obtained from maternity wards. Three R59W positive samples were
detected by SSCP analysis.
SSCP analysis can be seen as a mutation screening method as opposed to a
mutation detection method, as any change in the DNA sequence will be
observed. Gaunt et al. (2001) used SSCP analysis to screen 2 743 individuals in
order to detect new SNPs in the insulin-like growth factor 2 (IGF2) gene. In this
study, where we were only interested in the presence or absence of the R59W
mutation, verification of the result with a mutation detection method was essential
to ensure that the conformational change detected was indeed caused by the
R59W mutation. DNA from the three samples in which a change in DNA
sequence was found were re-isolated and digested with Styl RE, subsequent to
PCR amplification, to verify the presence or absence of the R59W mutation.
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Figure 3.4: SSCP analysis of samples amplified with the PP03F and PP03R primer pair. The R59W
mutation is present in sample 1 and absent in samples 2 - 9. N = a negative control for
PCR.
1 N 2 3 4 5 6 7 8 9
3.6.4 Comparison of Mutation Detection Systems
Of the three mutation detection systems used, ARMS is the quickest and most
cost effective method, as only a PCR reaction and subsequent agarose gel
electrophoresis is required. By adding EtBr to agarose gel mix, the gel can be
stained while electrophoresis is in progress, and visualization is done under UV
light upon completion of electrophoresis, eliminating the need for AgN03 staining.
No special equipment is necessary, and the relatively few steps in the process
minimize the likelihood of mistakes being made. Unfortunately, with the
conditions used in this study, this method was not as robust as would be
expected and subsequent testing with RE digestion was deemed necessary to
confirm the results obtained. However, retesting of the 1 419 samples with RE
digestion did not reveal any false positive or negative results, and the ARMS test
can thus be considered as a valid option for large scale mutation detection
studies. In future studies the sensitivity and specificity of the ARMS test can be
58
Stellenbosch University http://scholar.sun.ac.za
Chapter Three Results and Discussion
improved by the use of high fidelity Taq polymerases, although this would
increase the cost of the test.
RE digestion with Styl is a reliable method to detect the R59W mutation, as the
PCR amplicon used in this study included a control site to confirm successful
digestion, regardless of the R59W mutation status of the sample. Olynyk et al.
(1999) tested 3 011 samples for the hemochromatosis gene using RE digestion.
However, we found the Styl enzyme to be too expensive to use for the screening
of such a large quantity of samples. Furthermore the incubation step for RE
digestion was usually done overnight to ensure complete digestion. Mutation
detection via this system is thus time-consuming. There are also many pipetting
steps needed when performing RE digestion, rendering this procedure labour
intensive and increasing the possibility of mistakes to occur.
After initial screening of samples with Styl RE for comparative purposes, this
method of mutation detection was only used to verify R59W mutations found with
other methods. As only a few positive samples were found, it was not too
expensive or laborious to confirm these test results with Styl RE digestion.
SSCP analysis was found to be an effective method of screening for the R59W
mutation. It is a more time consuming method than ARMS (because silver
staining was used for visualization of the fragments obtained), but we found the
method to be robust and less time consuming than RE digestion. SSCP analysis
is also cheaper to perform than RE digestion.
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3.7 Results Obtained with Population Screening
A total of four R59W positive samples were found in this study:
1. A Caucasian male, Afrikaans-speaking, in the age group 21 - 40, obtained
from the Western Cape Blood Transfusion clinic cohort, with a known
family history of VP,
2. A Caucasian male, Afrikaans-speaking, newborn, obtained from a
maternity ward in the Western Cape, with a known family history of VP,
3. A Caucasian female, English-speaking, newborn, obtained from a
maternity ward in the Western Cape, with no family history of VP, and
4. A Caucasian female, Afrikaans-speaking, in the age group 41 - 59,
obtained from the Gauteng pathology clinics, with no family history of VP.
3.7.1 Screening Methodology
As porphyrin abnormalities may occur, among others, in cases of lead poisoning,
sideroblastic and haemolytic anaemia, iron deficiency, renal failure, cholestasis,
liver disease and gastrointestinal hemorrhage (Lim et a/., 1992) and certain diets,
it is possible that false positives can be diagnosed via biochemical testing.
Furthermore, even with current biochemical tests, many false positive results are
still reported (Kirsch et a/., 1998; Kotze et a/., 1998). Stool porphyrin levels do
not accurately reflect intracellular porphyrin concentrations, as normal fecal
porphyrin excretion has been demonstrated in the face of elevated biliary
porphyrin and porphyrinogen concentrations (Logan et a/., 1991; Kirsch et a/.,
1998).
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The biochemical method of VP detection used by Dean (1960) cannot distinguish
VP caused by the founder mutation and VP caused by other mutations, and thus
any individuals in the latter group, even though they are rare, would have been
counted as part of the founder mutation group, increasing the estimated
frequency of the founder mutation.
Calculation of the VP founder gene mutation frequency by means of a DNA
based test is more accurate than estimation by means of biochemical testing,
especially the qualitative methods used by Dean for the previous frequency
estimation (Kirsch et al., 1998; Kotze et al., 1998). The DNA tests are very
specific, as only the R59W mutation will be detected, and the patient's health
status or diet cannot influence the result of the test.
3.7.2 Study Populations
The study population used for the previous frequency determination of the
founder mutation causing VP was not unbiased. Dean (1960) expected a higher
concentration of porphyrics at the hospitals than in the general public because of
acute porphyric attacks. After obtaining a frequency of 1 in 250, he estimated
that 1 in 350 of the general public could have VP. This could still be an
overestimation of the frequency in the general population. Hift et al. (1997)
report that the frequency of porphyrics presenting with acute attacks have
decreased from 17%, prior to 1980, to only 9%. There was also a decline in the
total number of acute attacks of VP seen at Groote Schuur Hospital, from 56 in
the period 1957 to 1966 to 24 from 1988 to 1997.
61
Stellenbosch University http://scholar.sun.ac.za
Chapter Three Results and Discussion
The frequency estimated by Dean et al. in 1960 is also only representative of one
geographical area within South Africa (Eastern Cape). By obtaining samples
from various geographical areas as well as from multiple unbiased sources, a
more accurate estimation of the R59W mutation frequency can be made.
In the 1970's, blood donors who suffered from any of the porphyrias were
prohibited from donating blood, because fears existed that the disease, or
symptoms thereof, may be transferred to the receiver of the blood (personal
communication, Sr. Money, Western Cape Blood Transfusion Services). It may
be possible that, after these fears have been eradicated and individuals with
porphyria are permitted to donate blood again (only for the last couple of years),
these individuals, and maybe even their affected progeny, still do not donate
blood, making the group of samples obtained from the blood transfusion clinics
biased.
Pathology clinics may also not be a completely unbiased source for sample
collection, as pathology laboratories perform tests for porphyrias, and physicians
would refer patients suspected to have VP to the pathology laboratories to verify
the diagnosis.
Blood samples obtained from newborn babies may be the most unbiased group
of samples collected, as we strived to collect blood samples from all babies born
at the participating hospitals, irrespective of any conditions that the parents of the
baby might be suffering from, making this group more representative of the
population. If the R59W mutation was detected in a newborn sample and the
names and addresses of the patient and physician were provided, the latter was
requested to take a second blood sample from the baby, this time by means of a
heal prick. This was necessary to rule out the potential problem of motherly
contamination when obtaining a newborn's blood sample from the umbilical cord.
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By obtaining blood directly from the baby, the carrier status of the baby could be
confirmed.
One of the R59W positive samples obtained from a Caucasian newborn could
not be traced as the mother chose to participate anonymously. The parents of
the child indicated that their home language is English, but unfortunately the
ancestry of the patient could not be traced, nor could the parents be tested for
R59W or the test result confirmed in this case.
3.7.3 Screening of the Caucasian Population
In the total South African Caucasian study population, 0.12% (4 / 3 233) were
found to carry the R59W mutation (1 / 808). This newly obtained molecular
genetic frequency for the South African Caucasian population is remarkably
lower than the previously estimated frequency of 0.3% reported by Dean (1960),
established with biochemical testing of 6 458 individuals from the same
population group in the Eastern Cape.
Of 2 544 Afrikaans-speaking Caucasians screened, 3 (0.12%) were positive for
the R59W mutation. Two of these individuals had previous knowledge of their
VP carrier status or possible family history of VP.
In two of the four mutation-positive cases, the patient (or the newborn baby's
parents) was unaware of any cases of VP in their family. One of the two positive
adults had knowledge of his VP status, implying that 50% of the individuals in our
adult Caucasian study population were unaware of their carrier status, 30% lower
than the previously reported frequency of 80% (Day, 1986; Grandchamp et al.,
1996). The 50% penetrance is more in accordance with the figure of 60%
63
Stellenbosch University http://scholar.sun.ac.za
Chapter Three Results and Discussion
reported by Hift et al. (1997). Even though a family history of VP was known in
one of the two VP positive newborn babies, these cases were not included in our
penetrance estimation, as expression of VP symptoms only occur after puberty.
The Afrikaner founder mutation, R59W, was detected in one English-speaking
patient. This confirms that the mutation is not limited to the Afrikaner, but is also
present in the English-speaking population due to admixture with other, more
recent, immigrants. Three Afrikaner patients were mutation-positive, confirming
that the mutation is still more prevalent in the Afrikaner (Jenkins, 1996).
Of the 308 Afrikaner newborns tested, one (0.32%) was positive for the R59W
mutation, and in the total group of 379 Caucasian newborn samples, two (0.53%)
were positive for the R59W mutation. The frequency of the R59W mutation
obtained in the newborn cohort is even higher than Dean's estimated frequency
for the founder mutation. Even though this study population is very small, it is the
most unbiased group of samples.
Only one (0.05%) of 2 093 Caucasian samples obtained from blood transfusion
services was positive of the R59W mutation. The frequency of the mutation in
this group was expected to be lower than in the general population, as mentioned
in the previous section.
One (0.1%) of 761 samples obtained from Caucasians at pathology clinics tested
positive for the R59W mutation. The frequency of the mutation in this group was
expected to be higher than in the general population, as mentioned in the
previous section.
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3.7.4 Screening of Coloured and Black Populations
Samples from the mixed ancestry (Coloured) population included in this study
allowed us to determine the incidence of the R59W mutation in this population.
In a study conducted by Loubser et al., (1999), 236 apparently unrelated South
African patients of mixed ancestry with clinical features of familial
hypercholesterolemia (FH) were screened for the Afrikaner FH founder
mutations. Two common founder-related Afrikaner mutations, D206E and
V408M, were found in 14% of the patients in this study, and are attributed to
admixture of the populations. The R59W mutation has previously been detected
in a large VP family of mixed ancestry (Warnich, unpublished results), however,
no R59W positives were found in the group of 692 individuals of mixed ancestry
screened in this study. It can be expected that the frequency of the R59W
mutation in the Coloured population would be much lower than that found in the
South African Caucasian population. Because the Caucasian contribution to the
Coloured population was approximately 33% (Loubser et al., 1999), the
frequency of the R59W mutation is expected to be only a third of that found in the
South African Caucasian population. A much larger sample size will therefore be
needed to accurately approximate the frequency of the mutation in the population
of mixed ancestry.
The R59W mutation was not found in any of the 79 samples obtained from the
indigenous black population. VP is not prevalent among the black populations of
South Africa, and only one PPOX mutation (V290M) has been described in an
indigenous black South African (Corrigall et al., 2001). To date the R59W
mutation has never been reported in a black patient and admixture from the
Caucasian population is not evident at this stage.
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3.8 Ethical Issues
According to Mueller and Young (2001) a population screening program should
be presented in a fair and equitable way and should be morally acceptable to a
large proportion of the population to which it is offered. Participation to the
population screening should be completely voluntary and easily understood
information and well-informed counseling should both be readily available. This
study met all these requirements.
The positive mutation status of a voluntary blood donor was only revealed to the
individual via his or her physician and not directly to that individual (in cases
where results were requested). Disclosure of genetic screening results should
be accompanied by genetic counseling. If the physician was not qualified to
provide counseling, we suggested that the patient be referred to a genetic
counselor. If needed, we also offered to connect the physician with a qualified
genetic counselor in the area.
An ethical issue which arose in this study (and other similar studies) was that of
disclosure of a positive R59W mutation result when the individual, or the parents
of the individual (in the case of a newborn baby) did not require feedback
regarding the result. According to the Guidelines on Ethics for Medical Research
(compiled by the MRC, South Africa), "respect of persons, families and their
decisions according to the principles underlying informed consent" should be
applied. In the case of newborn babies the decision not to be informed regarding
the result of the R59W mutation test was made by the individual's parents, and
they, as legal guardians, speak on behalf and for the baby. In this study the
abovementioned guidelines were strictly followed and the decision of the
participants respected. However, lack of informed consent is sometimes justified
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if there is a clear benefit for genetic screening, e.g. all babies in the UK are
tested for phenylketonuria a few days after birth. No informed consent is
required as babies diagnosed with phenylketonuria can be effectively treated
(Smith, 1993).
A sample obtained from a newborn baby girl from one of the maternity wards in
the Western Cape tested positive for the R59W mutation, and the child's parents
indicated that they did not require to be informed regarding the result of the test.
It is my believe that by doing so the parents of this child did not distinctly request
that the result of the test be withheld from them, but rather to save time (the
second part of the informed consent form only had to be completed if a result
was required) or because of ignorance. Although information sheets were
provided to every participant, it is difficult to assess whether he/she understood
everything, especially the benefits associated with the test. This problem will
always be an issue when the geneticist conducting the research, or a genetic
counselor, is not present when the participants are approached. Early attempts
to introduce a sickle-cell carrier detection program in the black population of
North America had to be abandoned because of public criticism. The information
pamphlets tended to confuse the sickle-cell carrier status (which is usually
harmless) with the homozygous disease, which causes severe morbidity, leading
to employers and insurance companies discriminating against sickle-cell carriers
(Mueller and Young, 2001).
As knowledge regarding the positive R59W test result, accompanied by genetic
counseling, can prevent the individual from suffering a potentially fatal acute
attack caused by inappropriate drugs or other factors, every measure should be
taken to inform and educate patients in order to enable them to make informed
decisions.
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This study was conducted to estimate the incidence of the R59W founder
mutation in South Africa by means of molecular testing. The requirements for a
population screening study (listed on page 15 and 16), and the specific aims
(listed on page 26) have all been fulfilled:
• We believe that the benefits that follow from this study warrant the effort
and cost. Autonomy is enhanced, as individuals are better informed about
the genetic risks of VP (Mueller and Young, 2001). A positive test result
can be communicated by a genetic counselor and the necessary action be
taken. Skin symptoms can be prevented by taking the necessary
precautions and acute attacks can be evaded by avoiding known
precipitating factors. The prevention of morbidity and alleviation of the
suffering that the disease could impose is thus addressed.
• The project was ethically and socially acceptable, and approval of the
study, including sample collection, information forms and informed
consent forms, were obtained.
• VP information forms were designed to inform potential participants of the
project and to provide background information on VP in South Africa. A
shortened informed consent form was developed not to discourage
potential participants with the lengthy informed consent forms generally
used, to shorten the time needed to complete the form by maternity ward
personnel (in the case of sample collection from newborn babies) and also
to minimize the space needed for storage of the blood samples obtained.
These forms can be valuable when forms have to be designed for similar
screening projects.
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• Blood samples collected on FTA cards (Whatman BioScience) with
subsequent DNA isolation using FTA purification solution were found to be
the best collection and isolation methods to be used for this population
screening study. SSCP analysis was found to be the best suited mutation
detection system for this study, and positive results were confirmed using
RE analysis. We are thus confident that the DNA tests used are both
sensitive and specific.
• 4 072 samples were obtained from blood transfusion clinics, pathology
clinics and maternity wards in three provinces. A database was compiled
to record details obtained from the informed consent forms.
• The frequency of the VP founder mutation in the South African Caucasian
population is estimated as 0.12%, less than half of what was previously
estimated by Dean (1960) and in accordance with recent studies by De
Villiers et al. (unpublished results). However, different frequencies were
obtained within the various population samples. It is suggested that a
newborn baby population sample be used in the future, as it is the most
unbiased sample source. Interestingly, the highest frequency for the
R59W mutation was obtained in this sample.
• No R59W mutation-positive patients were found in the population of mixed
ancestry. The Caucasian contribution to this population is expected to be
± 33%, therefore the incidence of the R59W mutation in this population is
expected to be a third (0.04%) of the incidence in the South African
Caucasian population. Our preliminary results thus confirm the low
incidence of the R59W mutation in this population group, but a much
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larger sample size will be needed to accurately estimate the frequency of
the mutation in the population of mixed ancestry.
• Results obtained in this study also indicate that many individuals are
ignorant regarding their carrier status and are therefore at risk of suffering
potentially lethal acute attacks.
Future Study
These conclusions are based on a limited sample size, and in order to obtain a
more accurate estimation of the R59W frequency in South Africa, we suggest
that the number of individuals screened for the mutation should be increased to
include at least 10 000 individuals. In order to obtain a population sample that is
representative of the entire country, blood samples must be obtained from as
many geographical areas in South Africa as possible. It will be interesting to
compare the frequency of the R59W mutation in the various provinces of South
Africa. As the previous estimation of the founder mutation frequency was
performed on individuals living in the Eastern Cape, genetic screening of patients
residing in this province will be useful in assessing the accuracy of the
biochemically based study done by Dean (1960).
The infrastructure for collection of blood samples have been created during this
study, and the most effective collection, DNA isolation and molecular analysis
methods have been determined, ensuring rapid screening of numerous samples.
This estimated frequency of VP among South African Caucasians is still much
higher than in any other part of the world. It is thus important that the sample
size be increased in order to improve the accuracy of the founder mutation
frequency estimation in South Africa and to determine whether the issue of
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underdiagnosis and the resulting risk of potentially fatal acute attacks should be
addressed by appropriate genetic testing in the future.
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Variëgate Porfirie (VP) Navorsingsprojek
Wat is variëgate porfirie?
Variëgate porfirie, of VP, is 'n oorerflike siekte wat veroorsaak word deur 'n defek in een van die liggaam se essensiële
ensieme. Simptome ontwikkel gewoonlik eers na puberteit en sluit velskade, akute aanvalle en sensitiwiteit t.o.v. sekere
geneesmiddels in. Daar is beraam dat Suid-Afrika tussen 10 en 20 duisend VP lyers het, wat die hoogste voorkoms van VP
in die wêreld is.
Hoekom is die voorkoms van VP so hoog in Suid-Afrika?
Genealogiese navorsing het getoon dat die oorgrote meerderheid van VP lyers in Suid-Afrika afstammelinge is van 'n
egpaar (Adriana Jacobs, 'n weesmeisie van Holland, en Gerrit Janz van Deventer, 'n vryburger) wat in 1688 aan die Kaap in
die huwelik bevestig is. Een van hulle twee was vermoedelik die draer van die mutasie verantwoordelik vir die oorerflike
siekte en het dit na sommige van hulle agt kinders oorgedra, wat dit weer na hulle kinders oorgedra het, ens. Suid-
Afrikaanse wetenskaplikes het onlangs hierdie mutasie (die R59W mutasie) in meer as 90% van VP gevalle in ons land
geïdentifiseer, en die teenwoordigheid van die mutasie kan nou opgespoor word nog voordat enige simptome sigbaar is. Dit
beteken dat voorsorgmaatreëls in sulke gevalle getref kan word.
Wat is die simptome van VP?
Die uitdrukking van VP wissel aansienlik van pasiënt tot pasiënt, maar die mees algemeen is velsimptome en akute aanvalle.
Velsimptome kom veral voor op die dele wat aan die son blootgestel is. Die vel kan baie sonligsensitief en broos wees, en
dus maklik beseer word. Tydens'n akute aanval word erge buikpyne, naarheid en spierswakheid ondervind. Die inname
van sekere geneesmiddels, waar onder sommige narkosemiddels, anti-epileptiese middels, voorbehoedmiddels en
antibiotika, kan hierdie potensieel gevaarlike of selfs noodlottige akute aanvalle meebring. Ander faktore soos hormonale
veranderinge en verkeerde dieet kan egter ook 'n akute aanvalontlok. Dit is belangrik om te weet dat baie mense wat die
VP-mutasie dra nooit enige simptome van die siekte vertoon nie. Hierdie mense kan egter wel die siekte na hulle
kinders oordra en sommige van hulle mag wel simptome vertoon.
Wat is die doel van hierdie studie?
Met hierdie populasiesiftingstudie word beoog om die aantal VP lyers in ons land met meer akkuraatheid te beraam sonder
om, soos in die verlede, 'n moontlike sydige beraming te doen deur net gesertifiseerde kliniese gevalle te gebruik. Daar sal
veral gefokus word om te bepaal hoeveel mense in Suid-Afrika onbewus daarvan is dat hulle die porfirie mutasie dra en dus
onder meer die gevaar loop om geneesmiddels te gebruik wat tot akute aanvalle kan lei. Daar sal gepoog word om ongeveer
10 000 bloedmonsters van die naelstringe van pasgebore babas sowel as van donors by bloedbanke te neem en te ontleed vir
die teenwoordigheid van die R59W mutasie, ander VP mutasies en mutasies wat 'n uitwerking op die kliniese simptome van
die siekte mag hê.
Watter rol kan u speel?
Ons wil u vriendelik versoek om asseblief aan hierdie belangrike studie deel te neem. Op die invulstrokie kan u aandui of u
anoniem aan die projek wil deelneem of die uitslag van die R59W toets via u geneesheer wil bekom, in welke geval u u
persoonlike inligting sowel as die van u geneesheer moet invul en die toestemntingstrokie moet teken.
Hierdie projek is deur die Etiese Komitee van die Fakulteit Geneeskunde van die Universiteit van Stellenbosch goedgekeur,
en word finansieel deur die Mediese Navorsingsraad ondersteun. Die bloedmonster sal tans slegs gebruik word vir die
variegate porfirie navorsingsprojek, en die uitslag van die toets en enige verdere toetse sal uiters konfidensieel hanteer word.
Vir enige verdere inligting aangaande die projek, kontak gerus die studieleier, VP navorsingsprojek, by onderstaande adres.
- See reverse side for English version -
DEPARTEMENT GENETIKA, UNIVERSITEIT VAN STELLENBOSCH, J.C. SMUTS-GEBOU,
DE BEERSTRAAT, STELLENBOSCH, 7600 I PRIVAATSAK X1, MATIELAND, 7602
TEL. 021-8085839, FAKS: 021- 808 5833
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Variegate Porphyria (VP) Research Project
What is variegate porphyria?
Variegate porphyria, VP, is a heritable disease caused by a defect in one of the body's natural essential enzymes.
Symptoms develop fairly late in life after puberty and include various skin abnormalities, acute attacks and sensitivity
to certain medicines. It is estimated that South Africa has some 10-20 thousand VP sufferers, which is also the highest
incidence of VP known in the
world today.
Why is the incidence ofVP so high in South Africa?
Genealogical research shows that most VP sufferers in South Africa are probably descendants of Adriana Jacobs, a
Dutch orphan, and Gerrit Janz van Deventer, a free burgher, who married at the Cape in 1688. One of the two was a
carrier of the heritable mutation responsible for the disease and passed it on to future generations of the family through
one or more of their eight children. Scientists in South Africa have recently identified the mutation (the R59W
mutation) in more than 90% of VP cases occurring in South Africa and its presence in carriers can now be detected
even before the onset of disease symptoms. This means that precautionary measures can be taken in such cases.
What are the symptoms ofVP?
The expression of VP varies substantially from patient to patient, but generally it includes skin symptoms and acute
attacks. The skin is mostly affected in areas that are exposed to the sun, is very sensitive to UV light and extremely
fragile, so it is easily damaged or bruised. During acute attacks severe abdominal pains, nausea and muscle weakness
are experienced. The use of certain medications, among others certain types of anesthetics, anticonvulsants,
contraceptives and antibiotics can mediate these potentially dangerous or even deadly acute attacks. Other factors, for
example hormonal change or an excessive diet can also mediate acute attacks. It is important to know that it is
possible for carriers of the VP mutation not to experience any symptoms of the disease. These individuals can,
however, carry the disease over to their children, who may suffer from the VP symptoms.
What is the goal of this study?
The aim of this population survey is to obtain a better estimate of the frequency of VP sufferers and carriers of the VP
mutation in South Africa without the danger of bias from having to rely on certified clinical cases as in the past. The
main focus will now be on individuals who are unknowingly carriers of the porphyria mutation and for whom
precautionary measures to reduce the risk of suffering symptoms may be prescribed. The intention is to collect blood
samples from the umbilical cords of newborn babies as well as donors at blood banks and to screen samples for the
presence of the R59W mutation, as well as other VP mutations and mutations that may influence the clinical symptoms
of the disorder. A total sample size of around 10000 is envisaged.
What role can you play?
We would very much appreciate your participation in this very important study. On the submission form you can
indicate whether you would like to participate anonymously or be notified of the results of the R59W test via your
doctor, in which case you have to provide your personal details, as well as that of your doctor, and sign the consent slip.
This project was approved by the Ethics Committee of the Faculty of Medicine of the University of Stell enbosch, and is
financially supported by the Medical Research Council. The blood samples will currently only be used for the
variegate porphyria research project, and the results of this test and any other possible tests will be treated as highly
confidential. For any further information regarding this project, please contact the study leader, VP research project, at
the address below.
- Sien keersy vir Afrikaans -
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Variëgate Porfirie Projek
Departement Genetika
Universiteit van Stellenbosch
Naam van Hospitaal! Kliniek:
Geslag: OManIik o Vroulik
Ouderdom: oPasgebore 00-20 021-40 041-60 060+
Huistaal: o Afrikaans OEngels
oXhosa o Ander
Ras: OBIank o Kleurling o Swart
o Indiêr DAnder
Enige gevalle van porfirie
bekend in die familie? o Ja o Nee
Enige ander oorerflike o Nee o Ja* * lndien ja,
siektes bekend in die spesifiseer asb.
familie?
Verlang u die resultate van oNee o Ja* *Indien ja, voltooi
hierdie toets? keersyasb.
Hierdie kant hoef slegs voltooi te word indien u die uitslag van die toets verlang
Pasiênt inligting:
Naam: _
Adres: _
Tel no.:
Dokter aan wie resultate gestuur moet word:
Naam: _
Adres: _
Tel no.: _
Ingeligte toestemming:
Ek is tevrede dat ek ingelig is oor die variegate porfirie
mutasieopsporingsprojek. Hiermee verklaar ek my bereidwilligheid om deel te
neem aan die studie, en ek gee toestemming dat die bloedmonster deur my of
my kind geskenk vir hierdie navorsing gebruik mag word.
Handtekening Datum
Hierdie projek is deur die Etiese Komitee van die Fakulteit Geneeskunde van die
Universiteit van Stellenbosch goed gekeur. Monsters sal slegs vir die opspoor van
mutasies gebruik word. Alle inligting verskaf op die vorm, sowel as inligting bekom vanaf
die monsters sal konfidensieel hanteer word.
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Variegate Porphyria Screening Project
Department of Genetics
University of Stellenbosch
Name of Hospital! Clinic:
Gender: oMale D Female
Age: o Newborn 00-20 021-40 041-60 060+
Home
language: o Afrikaans D English
o Xhosa oOther
Race: oWhite DCaloured o African
o Indian DOther
Any known cases of
porphyria in the family? DYes DNa
Any other inherited diseases DNa o Yes* * If yes, please
In the family? specify
Results of this test required? DNa o Yes* *If yes, fill in
reverse side of
this form as well
This page has to be completed only if a result is required
Patient's information:
Name: _
Address: _
Tel no.: _
Medical practitioner to whom results must be sent:
Name: _
Address:
Tel no.: __
Informed consent:
I am satisfied that I have been informed about the variegate porphyria mutation
screening project. I hereby voluntarily agree to participate in this study and give
my consent that the blood sample I or my child donate(s) be utilised for this
research.
DateSignature
This project has been approved by the Ethics Committee of the Medical Faculty of the
University of Stellenbosch. Samples will only be used for the screening of mutations. All
information provided on form or obtained from samples will be treated confidentially.
94
Stellenbosch University http://scholar.sun.ac.za
